TW202008895A - Method for preparing health-care material by compounding fermented and lyophilized extract of Taiwan sea bream and extract of monostroma nitidum oligosaccharides for providing a composite material rich in high-quality active peptides with low molecular weight - Google Patents

Method for preparing health-care material by compounding fermented and lyophilized extract of Taiwan sea bream and extract of monostroma nitidum oligosaccharides for providing a composite material rich in high-quality active peptides with low molecular weight Download PDF

Info

Publication number
TW202008895A
TW202008895A TW107128857A TW107128857A TW202008895A TW 202008895 A TW202008895 A TW 202008895A TW 107128857 A TW107128857 A TW 107128857A TW 107128857 A TW107128857 A TW 107128857A TW 202008895 A TW202008895 A TW 202008895A
Authority
TW
Taiwan
Prior art keywords
qinghai
extract
vegetable
sea bream
freeze
Prior art date
Application number
TW107128857A
Other languages
Chinese (zh)
Other versions
TWI702006B (en
Inventor
龔瑞林
陳冠文
潘崇良
Original Assignee
龔瑞林
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 龔瑞林 filed Critical 龔瑞林
Priority to TW107128857A priority Critical patent/TWI702006B/en
Publication of TW202008895A publication Critical patent/TW202008895A/en
Application granted granted Critical
Publication of TWI702006B publication Critical patent/TWI702006B/en

Links

Images

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a method for preparing health-care material by compounding fermented and lyophilized extract of Taiwan sea bream and extract of monostroma nitidum oligosaccharides. The method is provided to extract the by-products remained from processing frozen Taiwanese sea bream fillets by hot extraction, and then to use two kinds of lactic acid bacteria to perform fermentation and lyophilizing treatment on the extract for a predetermined period of time so as to obtain fermented and lyophilized extract of Taiwan sea bream. For monostroma nitidum, after thermal extraction, the extracts are hydrolyzed and lyophilized with a microbial enzyme for a predetermined period of time to obtain extract of monostroma nitidum oligosaccharides. Finally, the fermented and lyophilized extract of Taiwan sea bream and the extract of monostroma nitidum oligosaccharides are compounded into a composite material at a predetermined weight percentage. As such, the composite material not only is rich in high-quality active peptides with low molecular weight to provide the effect of effectively suppressing the increase in blood pressure, but also has better ACE inhibitory efficiency than the fermented and lyophilized extract of Taiwan sea bream and the extract of monostroma nitidum oligosaccharides themselves.

Description

由臺灣鯛發酵凍乾萃取物與青海菜寡醣萃取物複合成保健材料之製法 Method for preparing health-care material from Taiwan sea bream fermented freeze-dried extract and Qinghai vegetable oligosaccharide extract

本發明係關於一種活性胜肽複合材料的製法,尤指一種由臺灣鯛(Tilapia)加工後副產品經發酵及培養萃取出之活性胜肽與青海菜寡醣萃取物複合成為一複合材料的製法,以期能充分利用臺灣鯛養殖業者根據多年來豐富且嚴謹的養殖知識、經驗及辛勤付出所養成之臺灣鯛優質魚肉,及臺灣鯛加工業者根據多年來豐富且嚴謹之加工知識、經驗及辛勤付出而能在對臺灣鯛加工後所殘留優質之副產品(即,臺灣鯛冷凍魚片加工後之殘留物,含有魚骨、魚皮、魚鱗及殘肉...等物質之殘留物),據以培養及製造出高品質的活性胜肽,再加上青海菜寡醣萃取物,而令所複合而成之複合材料能因彼此內活性胜肽間所產生的協同作用,而使得該複合材料具備更佳的保健作用及效果,從而令其得以被選擇作為高品質化粧品或保健食品(用以預防高血壓、心力衰竭、2型糖尿病及腎病等疾病)的主要成份,以佳惠及確保消費者皮膚及身體的健康,進而令臺灣鯛冷凍魚片加工後所殘留的優質副產品及臺灣沿海垂手可得的青海菜,能因本發明而獲得更高附加價值的利用。 The invention relates to a method for preparing an active peptide composite material, in particular to a method for preparing a composite material in which the active peptide extracted by fermentation and cultivation of by-products from Taiwan sea bream (Tilapia) is fermented and cultured to form a composite material. In order to make full use of Taiwan sea bream aquaculture operators based on years of rich and rigorous breeding knowledge, experience and hard work to develop Taiwan sea bream quality fish meat, and Taiwan sea bream processing industry based on years of rich and rigorous processing knowledge, experience and hard work It can cultivate high-quality by-products left after processing Taiwan sea bream (that is, the residuals of Taiwan sea bream frozen fish fillet processing, containing fish bones, fish skin, fish scales and residual meat... etc.), based on cultivation And the production of high-quality active peptides, coupled with the oligosaccharide extract of Qinghai vegetables, so that the composite materials can be synergistic due to the synergy between the active peptides in each other, so that the composite material has more Good health care effect and effect, so that it can be selected as the main component of high-quality cosmetics or health foods (to prevent diseases such as high blood pressure, heart failure, type 2 diabetes, and kidney disease) to protect consumers’ skin and The health of the body, in turn, enables the high-quality by-products remaining after the processing of Taiwan sea bream frozen fish fillets and the Qinghai vegetables readily available on the coast of Taiwan to be used for higher added value due to the present invention.

按,肽(peptide,係來自希臘文的「消化」一字),亦即目前所稱之「胜肽」,又稱「縮氨酸」,是天然界存在的一種小生物分子,介 於胺基酸(amino acid)和蛋白質之間的物質,其中,胺基酸之分子最小,蛋白質之分子最大,而「胜肽」則是胺基酸單體組成之短鏈,由肽(醯胺)鍵連接。當一個胺基酸之羧基基團與另一個胺基酸之氨基反應時,即會形成共價化學鍵。肽由胺基酸組成之短鏈是精準的蛋白質片段,其分子只有奈米般大小,極容易被腸胃、血管及肌膚吸收。一般言,2胜肽(簡稱2肽),就是由二個胺基酸組成之蛋白質片段,由兩個或兩個以上胺基酸脫水縮合形成若干個肽鍵從而組成一個肽,多個肽進行多級摺疊就組成了一個蛋白質分子,因此,蛋白質有時也被稱為「多肽」;常見的胜肽有2肽(dipeptide)、3肽(tripeptide),甚至多肽(polypeptide)等,其中,2~20肽屬於寡肽(oligo-peptide),20~50肽屬於多肽,通常10肽以下者較具醫藥及商業實用性。 Press, peptide (from the Greek word "digestion"), also known as "peptide", also known as "peptide", is a small biological molecule in nature, between amines The substance between amino acid and protein. Among them, the amino acid has the smallest molecule and the protein has the largest molecule. The "peptide" is a short chain composed of amino acid monomers. It consists of a peptide (acylamine) Key connection. When the carboxyl group of one amino acid reacts with the amino group of another amino acid, a covalent chemical bond is formed. The short chain of peptides composed of amino acids is a precise protein fragment. Its molecules are only nano-sized, and are easily absorbed by the stomach, blood vessels and skin. Generally speaking, 2 peptides (referred to as 2 peptides) are protein fragments composed of two amino acids. Two or more amino acids are dehydrated and condensed to form several peptide bonds to form a peptide. Multi-level folding constitutes a protein molecule. Therefore, proteins are sometimes called "polypeptides"; common peptides include 2 peptides (dipeptide), 3 peptides (tripeptide), and even polypeptides (polypeptide). Among them, 2 ~20 peptides belong to oligo-peptides, 20~50 peptides belong to polypeptides, usually those with 10 peptides or less are more medically and commercially practical.

查,「胜肽」可由膳食蛋白質(dietary protein)通過化學方法水解出來,也可以人工方法取得。誠如前述,胜肽係由兩個或兩個以上之胺基酸(amino acid)聚合而成,故,其在細胞生理及代謝功能之調節上甚為重要,但是,由於胜肽的性質大多不太穩定,因此,若欲長期貯存,宜被放置在具防潮機制且溫度維持在攝氏4℃以下之環境中。另,根據目前的許多研究顯示,活性肽與生物體的營養、荷爾蒙、酵素抑制、免疫調節、抗菌、抗病毒、抗氧化等機能有著非常緊密之關係。請參閱第1圖所示,肽是由胺基酸之胺基(-NH2)與羧基(-COOH)脫水縮合而形成肽鍵後所形成之鏈狀分子,其中,肽鍵是由一個胺基酸與次一個胺基酸的胺基,行脫水縮合反應而成的-CO-NH-鍵,具有雙鍵的性質,且與鄰近共六個原子位在同一平面,因此,C-N不可自由轉動,肽鍵是構成蛋白質架構之連繫帶。 Check, "peptide" can be dietary protein (dietary protein) hydrolyzed by chemical methods, can also be obtained manually. As mentioned above, peptides are formed by the polymerization of two or more amino acids. Therefore, they are very important in the regulation of cell physiology and metabolic function. However, due to the nature of peptides It is not very stable, so if you want to store it for a long time, it should be placed in an environment with a moisture-proof mechanism and the temperature maintained below 4℃. In addition, according to many current studies, active peptides have a very close relationship with organisms' nutrition, hormones, enzyme inhibition, immunomodulation, antibacterial, antiviral, and antioxidant functions. As shown in Figure 1, the peptide is a chain molecule formed by dehydrating and condensing an amine group (-NH2) of an amino acid and a carboxyl group (-COOH) to form a peptide bond, wherein the peptide bond is composed of an amine group The -CO-NH- bond formed by the dehydration condensation reaction between the acid and the amine group of the next amino acid has the property of a double bond, and is in the same plane with a total of six adjacent atoms. Therefore, CN cannot rotate freely. Peptide bonds are the connecting bands that make up the protein architecture.

對於含半胱氨酸,甲硫氨酸或色氨酸的肽,脫氧緩衝劑對其溶解必不可少,這類肽易在於空氣中氧化。含穀氨醯胺或天冬醯胺的多肽也容易降解。多肽在-20℃很穩定,特別是冷凍乾燥並保存在乾燥器中,在將它們暴露於空氣之前,冷凍乾燥之多肽可以放於室溫。 For peptides containing cysteine, methionine or tryptophan, deoxygenated buffers are essential for their dissolution. Such peptides are susceptible to oxidation in the air. Peptides containing glutamine or aspartame are also easily degraded. Peptides are very stable at -20°C, especially freeze-dried and stored in a desiccator. Before exposing them to air, freeze-dried polypeptides can be placed at room temperature.

一般言,胜肽是生物體最重要的『直接營養素』,可以說『沒有胜肽,就沒有生態!』,『胜肽』是一種分子量很小、必需由胺基酸結合而成的天然物質、只需微量就具有極強的生理功能及活性,這一點與生物體之賀爾蒙功能類似。一般生物體在分解食物中的蛋白質時,必須經過多種酵素的輔助,才可令蛋白質被分解及吸收,現在以「胜肽」的結構觀之,因其分子極小,故很容易被生物體完全地吸收,其被人體吸收的比率是一般蛋白質的5倍。例如:人體中的胰島素及大腦中的腦啡就是一種胜肽化合物,人體部份中荷爾蒙亦是由胜肽所構成,而支鏈型胺基酸胜肽(BCAA)、酪蛋白磷酸胜肽(CPP)、麩醯胺胜肽(Glutamine Peptide)....等均為胜肽。人體內約有一萬多種胜肽,各該胜肽是人體經由對一般食物的消化、水解、吸收及利用後自體合成(並非分泌)者,合成不敷使用時,最佳的方法就是直接補充所需的胜肽!雖然,在人體及諸多動物體內,可以通過胃、胰腺分泌的胃蛋白酶和胰蛋白酶等來分解食入的蛋白質,從而形成肽類物質。但是,能從食物中直接攝取到的胜肽數量實在極為少數,其重要的原因,是人體及動物體對所需的酶具有專一性,此亦導致人體及諸多動物體無法自身產生功能足够且多樣的功能肽,據此,無論從數量上,抑或從種類上,都證明現代人的食物中確實極缺乏人體所需的多種胜肽。此外,透過現代科學的實驗及測試亦證明,胜肽的吸收機制具有下列的諸多特點: 1、胜肽無需人體及動物體的消化,即能被直接吸收;2、人體及動物體對胜肽的吸收速極快;3、人體及動物體在吸收胜肽時,胜肽不會遭到破壞;4、胜肽具有100%被人體及動物體吸收的特點;5、胜肽具有主動地被人體及動物體吸收的特點;6、胜肽具有優先被人體及動物體吸收的特點;7、人體及動物體對胜肽的吸收,具有無需耗費人體及動物體能量,完全不會增加消化道負擔的特點,特別是具有完全不會增加胃腸功能負擔的特點;8、胜肽在人體及動物體能表現出載體的作用,可將平常人所食入的營養物質,特別是鈣等對人體及動物體有益的微量元素,吸附、沾粘、承載在載體上;及9、胜肽可在人體及動物體內發揮運輸工具的作用。 In general, peptides are the most important "direct nutrients" of an organism. It can be said that "without peptides, there is no ecology!" ""Peptide" is a natural substance with a small molecular weight, which must be combined with amino acids. It has very strong physiological functions and activities in only a small amount, which is similar to the hormone function of living organisms. In general, when an organism decomposes the protein in food, it must be assisted by a variety of enzymes, so that the protein can be decomposed and absorbed. Now the structure of the "peptide" is considered, because its molecule is extremely small, it is easy to be completely The rate of absorption by the human body is 5 times that of ordinary protein. For example, insulin in the human body and enkephalin in the brain are a kind of peptide compound. Hormones in the human body are also composed of peptides, and branched chain amino acid peptides (BCAA) and casein phosphopeptides ( CPP), Glutamine Peptide, etc. are all peptides. There are more than 10,000 kinds of peptides in the human body. Each of these peptides is synthesized by the human body (not secreted) after digestion, hydrolysis, absorption and utilization of general food. Directly supplement the required peptides! Although, in the human body and many animals, pepsin and trypsin secreted by the stomach and pancreas can break down ingested proteins, thereby forming peptide substances. However, the number of peptides that can be directly ingested from food is extremely small. The important reason is that the human body and animal body are specific to the required enzymes. This also causes the human body and many animal bodies to be unable to produce sufficient functions on their own. A variety of functional peptides, based on this, no matter in quantity or in type, it proves that the foods of modern people are really lacking in the variety of peptides required by the human body. In addition, the experiments and tests of modern science also prove that the absorption mechanism of peptides has the following characteristics: 1. Peptides can be directly absorbed without the digestion of human and animal bodies; 2. The peptides of human and animal bodies The absorption rate is extremely fast; 3. When the human body and animal body absorb the peptide, the peptide will not be destroyed; 4. The peptide has the characteristics of 100% absorption by the human body and animal body; 5. The peptide has the initiative to be absorbed Absorption characteristics of human body and animal body; 6. Peptide has the characteristic of being preferentially absorbed by human body and animal body; 7. Absorption of peptide by human body and animal body has no need to consume energy of human body and animal body and will not increase digestive tract at all The characteristics of the burden, especially the feature that it does not increase the burden of gastrointestinal function at all; 8. Peptide shows the role of a carrier in human and animal physical performance, and can absorb the nutrients ingested by ordinary people, especially calcium, etc. The beneficial trace elements of the animal body are adsorbed, adhered, and carried on the carrier; and 9. Peptide can play a role as a means of transportation in the human body and animal body.

按,追溯胜肽的歷史,最早是於1980年初,從人體血漿中分離出來的生長因子,其實就是蛋白質的一個片段3胜肽。直到2002年7月2日,在巴黎舉辦的第20屆皮膚科醫學大會中,始透過研究及實驗印證了,對照維他命A、C,屬於寡胜肽之5胜肽具有更顯著的除皺功效。自此以後,在歐美抗老保養品中,胜肽即一躍而成為主流的成份。不僅達文西密碼有待解釋,近年來,胜肽保養品也伴隨著數字密碼現身!事實上,胜肽係由蛋白質的一小片段,藉由不同數字、種類的胺基酸所組合而成,不同數字所代表的,就是由幾個胺基酸組成,藉由胺基酸序列的不同,即能對應於肌膚的不同需求。相對於膠原蛋白這類分子較大的美容成分,由十個以內 胺基酸組成的寡胜肽成份,其分子相當於奈米級,所以非常容易被肌膚吸收。例如:5胜肽就是由5個不同胺基酸所組成,目前,胜肽數字從2~100皆有,已經被運用至保養品的胜肽則有2、3、4、5、6、7、9等胜肽成份;很多人以為胜肽數字越大,效果就越好,其實這是一個錯誤的觀念,事實上,其數字所代表的意義,是數字越小,越容易被肌膚吸收。數字大小,也代表著作用於肌膚深淺部位的不同,例如:2、3、4、5、6等胜肽,皆具有能促進膠原蛋白增生的功能,作用位置則集中在纖維母細胞,而分子較大些的7、9胜肽,主要目的為抗自由基、美白、保濕、滋潤,作用於表皮層正是恰如其分,作用於纖維母細胞反而較沒意義。 According to the history of peptides, the earliest is the growth factor isolated from human plasma in the early 1980s, which is actually a peptide 3 fragment of a protein. Until July 2, 2002, in the 20th Dermatology Congress held in Paris, it was confirmed through research and experiments that compared with vitamins A and C, 5 peptides belonging to oligopeptides have more significant wrinkle-reducing effect . Since then, peptides have become the mainstream ingredient in anti-aging skin care products in Europe and America. Not only is the Da Vinci code yet to be explained, in recent years, peptide care products have also appeared with digital codes! In fact, peptides are composed of a small piece of protein, which is composed of different numbers and types of amino acids. The different numbers represent several amino acids, which are composed of amino acid sequences. Different, can correspond to different needs of the skin. Relative to cosmetic components with large molecules such as collagen, oligopeptide components composed of ten or less amino acids have molecules equivalent to nanometers, so they are easily absorbed by the skin. For example: 5 peptides are composed of 5 different amino acids. At present, the number of peptides is from 2 to 100, and the peptides that have been used in maintenance products are 2, 3, 4, 5, 6, and 7. , 9 and other peptide components; many people think that the larger the peptide number, the better the effect. In fact, this is a wrong concept. In fact, the meaning of the number is that the smaller the number, the easier it is to be absorbed by the skin. The size of the number also represents the difference in the depth and depth of the skin. For example, peptides such as 2, 3, 4, 5, and 6 all have the function of promoting collagen hyperplasia, and the focus is on fibroblasts, while the molecules The larger peptides 7 and 9 are mainly for anti-free radicals, whitening, moisturizing and moisturizing. It acts just right on the epidermis, and it is less meaningful to act on fibroblasts.

此外,著名的la prairie實驗室亦發現,抗老的第一步就是要解決「慢性無徵兆發炎」(Chronic Silent Inflammation,簡稱C S I)的現象,這是美容醫學界近兩年來最新發現的一種老化現象,一般人的肉眼完全不會察覺到此種老化現象,但是,它卻會直接侵害到肌膚底層,且每個人都會受到CSI的威脅。尤其是,過了20歲後,在羰基化、醣化、氧化三種反應交互作用的影響下,就會引發CSI現象,2胜肽則正是能抑制羰基化、醣化、氧化的幕後推手;3胜肽的功能則是能促進纖維母細胞膠原蛋白的增生,3胜肽是胜肽中最早被發現的一種胜肽排列組合方式,據此,業界第一支加入胜肽的保養品為「露得清緊緻活力眼霜」,其中所含的「活性酮」配方,指的就是「3胜肽」;至於4胜肽,則是1990年自傷口癒合組織中被分離出來者,具有抗發炎、增強肌膚耐受力、促進傷口癒合及增生的功效。人體內存在的青春荷爾蒙基轉被稱為DHEA,這種荷爾蒙會隨著年齡增長而遞減,4胜肽恰可補足因年齡增長而遞減的DHEA,且能增加人體對外界環境變化 (如:污染)的防禦能力;5胜肽的功能則係在刺激膠原蛋白的增生,且係最早被皮膚科醫學界拿來與維他命A等抗老成分搭配,標榜可以直接作用於真皮層,促進膠原蛋白增生,達到緊實肌膚目的的成份,與其他保濕成分相佐,尚可加速緊緻拉提之效果;6胜肽的功能係在舒緩表情紋,又被稱為類肉毒桿菌素,具有抑制神經物質過度釋放、影響皮下神經與肌肉間傳遞蛋白的作用,對於減緩臉部的魚尾紋、法令紋等動態紋路效果最好,法國皮膚科醫師研究,6胜肽運用於消除眼周皺紋的效果尤其明顯;9胜肽的功能係在能減少黑色素的合成及製造,當肌膚受到外界刺激或紫外線照射時,位於基底層細胞內的α-促黑激素便會與黑色素細胞上的接受器結合,直接刺激黑色素細胞,活化酪胺酸脢,開始分泌黑色素,9胜肽便能在黑色素形成的源頭進行阻斷、中止α-促黑激素訊息的傳導,避免其與黑色素細胞上接受器結合,以降低黑色素生成的機會。針對胜肽使用於化妝及保養的訣竅,中國醫藥大學藥用化妝品學系助理教授尤善臻亦指出,作用於「眼周」的胜肽產品堪稱是投資報酬率最高的保養品,因為,比起臉部或身體其他肌膚來說,眼周肌膚脂肪層及組織都較薄,加上胜肽分子小,滲透力高,短時間內就能看到效果;另外,為了讓價值不菲的胜肽成份能被更有效地吸收,他亦建議在使用胜肽產品前應先將臉清洗乾淨後再塗抹,以避免皮膚可能分泌之殺菌物質,令胜肽成份產生變化。最後,夜晚為細胞活躍時段,相較於白天,在夜晚使用胜肽產品的效果也會隨之提高。 In addition, the famous la prairie laboratory also found that the first step in anti-aging is to solve the phenomenon of "Chronic Silent Inflammation" (CSI), which is the latest discovery of aging in the aesthetic medicine industry in the past two years Phenomenon, the average person will not be aware of this aging phenomenon, but it will directly invade the bottom of the skin, and everyone will be threatened by CSI. In particular, after the age of 20, under the influence of the interaction of the three reactions of carbonylation, saccharification, and oxidation, the CSI phenomenon will be triggered. 2 peptides are the behind-the-scenes pushers that can inhibit carbonylation, saccharification, and oxidation; 3 wins The function of the peptide is to promote the proliferation of fibroblast collagen. 3 peptides are the earliest peptide arrangement and combination method found in peptides. According to this, the industry's first maintenance product that incorporates peptides is "Lulu Tightening" "Rejuvenating Eye Cream", which contains the "active ketone" formula, refers to "3 peptides"; as for 4 peptides, it was isolated from the wound healing tissue in 1990, with anti-inflammatory and enhance skin resistance The effect of stress, promoting wound healing and hyperplasia. The conversion of youth hormones present in the body is called DHEA. This hormone will decrease with age. 4 peptides can just make up for DHEA that decreases with age, and can increase the body's changes to the external environment (such as pollution ) Defense ability; the function of 5 peptides is to stimulate collagen hyperplasia, and it is the earliest dermatology medical industry to use it with vitamin A and other anti-aging ingredients, advertised that it can directly act on the dermis layer to promote collagen hyperplasia , The ingredients that achieve the purpose of firming the skin, combined with other moisturizing ingredients, can still accelerate the effect of tightening and lifting; the function of 6 peptides is to soothe expression lines, also known as botulinum-like, with nerve suppression The excessive release of substances affects the transfer protein between the subcutaneous nerves and muscles. It has the best effect on slowing the dynamic lines such as crow's feet and decree lines. French dermatologists have studied that 6 peptides are particularly effective in eliminating wrinkles around the eyes. ; The function of 9 peptides is to reduce the synthesis and production of melanin. When the skin is exposed to external stimulation or ultraviolet radiation, the alpha-melanotropin located in the basal layer cells will combine with the receptor on the melanocytes to directly stimulate Melanocytes, which activate tyrosinase, begin to secrete melanin, 9 peptides can block the source of the formation of melanin, stop the transmission of α-melanotropin signal, and avoid its combination with the receptor on the melanocyte to reduce melanin Generated opportunities. Regarding the know-how of using peptides in makeup and maintenance, You Shanzhen, an assistant professor in the Department of Pharmaceutical Cosmetics of China Medical University, also pointed out that the peptide products acting on the "eyes" can be called the maintenance products with the highest return on investment, because, Compared to the face or other skin of the body, the fat layer and tissues around the eye are thinner, and the peptide molecule is small, the penetration is high, and the effect can be seen in a short time; in addition, in order to make it valuable Peptide ingredients can be absorbed more effectively. He also suggested that the face should be cleaned and applied before using peptide products to avoid possible bactericidal substances secreted by the skin and make the peptide ingredients change. Finally, the night is a period of active cells. Compared with the daytime, the effect of using peptide products at night will also increase.

「活性胜肽」是組成細胞的最基礎元素,相當於細胞的總司令、總調度者,身體哪個地方出現了缺陷?或細胞受損了?總司令就會馬上執行調控,帶著各種營養物質去修復受損或病變的細胞,當組成這些器 官組織的細胞都變好了,器官組織的健康問題自然也就獲得解決了。據此,年輕時,因「活性胜肽」的製造能力充足,故身體健康且體力充沛,過了40歲,身體將因製造「活性胜肽」的能力驟降,而缺乏「活性胜肽」,從此,各種慢性疾病乃隨之而來!這也就是為什麼補充「活性胜肽」能讓三高(高血壓、高血壓及高血脂)、白內障、骨關節...等病症獲得良好地控制,從而使病患白髮轉黑、精力變得充沛的重要原因。「活性胜肽」對人體有什麼作用?在人體的生命活動中,因細胞發生突變,而導致細胞出現異常現象,實乃經常會發生的自然現象,這也是人體內外部多種因素錯綜複雜綜合作用的結果。從內部來說,受精卵從一個細胞變成幾千億個細胞約要歷經幾億次的細胞分裂,每次細胞分裂時每條單鏈的DNA會複製出各別的另一條,只要有分裂,就會有發生錯誤的幾率。雖然,細胞變異、細胞出現錯誤的現象是經常發生的自然現象,但是,為什麼我們每個人大都仍然能正常地從小活到老?這就是「活性胜肽」的機能及作用。「活性胜肽」就是控制人體生命活動的司令部,也就是人體這座大廈的總調節師,正是因為有了「活性胜肽」的存在,才保證了生命體各種組織的各項正常活動,該合成時合成!該複製時複製!更關鍵的是如何合成及複製?都需要透過「活性胜肽」的指揮與調度,因此,「活性胜肽」實乃人體細胞調節的總工程師,人體由無數個細胞所組成,因此,細胞的健康自然決定了器官組織的健康。查,代表美國最高醫療水平的「杜克大學醫學院」曾針對「活性胜肽」展開大規模的臨床實驗,其中,克拉茲教授的實驗團隊,在對腦中風病患所進行的實驗組與對照組的實驗結果中清楚顯示,補充「活性多胜肽」組的病患中,罹患高血壓、冠心病及糖尿病等病症的患者用藥量平均減少了三分之 二,仍然能維持各項生理指標的平穩及身體的健康,罹患惡性腫瘤、肝硬化、肝腹水等病症的病患存活率亦提升了79%,罹患慢性呼吸系統疾病、慢性腸胃病等病症的其他患者,在補充「活性多胜肽」營養品後,身體狀況也有大幅好轉的跡象! The "active peptide" is the most basic element that constitutes a cell. It is equivalent to the commander-in-chief and general dispatcher of the cell. Where is the body defective? Or the cells are damaged? The commander-in-chief will immediately carry out regulation and take various nutrients to repair damaged or diseased cells. When the cells that make up these organs are all better, the health problems of organs and tissues will naturally be solved. According to this, when young, due to the sufficient manufacturing capacity of "active peptides", the body is healthy and full of energy. After 40 years of age, the body will lack the "active peptides" due to the sudden decline in the ability to manufacture "active peptides" Since then, various chronic diseases have followed! This is why supplementing with "active peptides" can make the three high (hypertension, hypertension and hyperlipidemia), cataracts, bones and joints and other diseases under good control, so that the patient's white hair turns black and energy changes An important reason for being abundant. What does "active peptide" do to the human body? In the life activities of the human body, mutations in cells cause abnormal phenomena in the cells. This is a natural phenomenon that often occurs. This is also the result of the intricate and comprehensive effect of various factors inside and outside the human body. Internally, it takes about hundreds of millions of cell divisions for a fertilized egg to change from a cell to hundreds of billions of cells. Each time a cell divides, each single-stranded DNA will be copied into another one, as long as there is a division, There will be a chance of error. Although the phenomenon of cell mutation and cell error is a natural phenomenon that often occurs, why do most of us still live normally from small to old? This is the function and function of "active peptide". "Active peptide" is the headquarters that controls human life activities, that is, the chief regulator of the human body building. It is precisely because of the existence of "active peptide" that the normal activities of various organizations of the living body are guaranteed. , The synthesis when the synthesis! Copy when copying! More critical is how to synthesize and copy? All need to be commanded and dispatched by "active peptide". Therefore, "active peptide" is actually the chief engineer of human cell regulation. The human body is composed of countless cells. Therefore, the health of cells naturally determines the health of organs and tissues. Zha, the Duke University School of Medicine, which represents the highest medical level in the United States, has launched a large-scale clinical experiment on "active peptides". Among them, the experimental team of Professor Kratz, in the experimental group of patients with stroke The experimental results of the control group clearly show that the patients in the group supplemented with "active multi-peptide" suffered from hypertension, coronary heart disease, diabetes and other diseases. The stability of the index and the health of the body have increased the survival rate of patients suffering from malignant tumors, cirrhosis, liver ascites and other diseases. Other patients suffering from chronic respiratory diseases, chronic gastrointestinal diseases and other diseases are After the "peptide" nutrition, there are signs of a substantial improvement!

既然,「胜肽」在皮膚美容及身體保養上具有前述其它物質所無法替代的諸多優異功能,且「胜肽」可由膳食蛋白質(dietary protein)通過化學方法水解出來,據此,如何在眾多膳食蛋白質(dietary protein)中挑選出一種價廉物美的優質膳食蛋白質?並據以製作出優質的「活性胜肽」,即成為近年來相關胜肽產品業界始終汲汲營營、不斷探索、努力研究開發,以期能獲得突破之一共同議題,亦為本發明在後續內容中亟欲探討及克服之一重要課題。 Since "peptide" has many excellent functions that can not be replaced by other substances in skin beauty and body care, and "peptide" can be hydrolyzed by dietary protein by chemical methods, according to this, how to Choose a cheap, high-quality dietary protein from dietary protein? Based on this, the production of high-quality "active peptides" has become a common topic in the related peptide product industry in recent years, which has always drawn on the camp, continued exploration, and hard research and development in order to achieve breakthroughs. One of the most important topics to be discussed and overcome is urgently needed.

有鑑於前述「活性胜肽」之諸多優異特性,發明人經過長久努力研究與實驗,終於開發設計出本發明之一種「由臺灣鯛發酵凍乾萃取物與青海菜寡醣萃取物複合成保健材料之製法」,以期藉由本發明的提出,能有效利用臺灣鯛產業加工後所遺留下來價廉物美且品質優異的副產品中優質之膳食蛋白質,藉添加青海菜寡醣萃取物(Extraction of Monostroma nitidum oligosaccharides,以下簡稱MO),令二者複合後,能據以製作出品質優異且價格合宜的「活性胜肽」複合材料,從而能佳惠對優質「活性胜肽」產品有迫切需求的普羅大眾。 In view of the many excellent characteristics of the aforementioned "active peptides", after long-term hard research and experiment, the inventor finally developed and designed a "health material made from fermented freeze-dried extract of Taiwan sea bream and oligosaccharide extract of Qinghai vegetable into a health care material. With the proposal of the present invention, it is possible to effectively use the high-quality dietary protein in the by-products of cheap, high-quality and high-quality leftover from the processing of the Taiwan sea bream industry, by adding the Extract of Monostroma nitidum oligosaccharides , Hereinafter referred to as MO), after the two are combined, we can produce "active peptide" composite materials with excellent quality and reasonable price, so that Jiahui can provide the general public with an urgent need for high-quality "active peptide" products.

本發明之主要目的,係提供一種由臺灣鯛發酵凍乾萃取物與青海菜寡醣萃取物複合成保健材料之製法,該製法係將臺灣鯛(Tilapia)冷凍 魚片加工後殘留之副產品(為臺灣鯛冷凍魚片加工後之殘留物,如:含有魚骨、魚皮、魚鱗及殘肉...等物質的殘留物)利用熱萃取方式進行萃取後,使用兩種乳酸菌分別對其萃取物執行一預定期間的發酵及凍乾處理,以獲得臺灣鯛發酵凍乾萃取物(Extraction of fermented Tilapia,以下簡稱EFT);針對青海菜(Monostroma nitidum)進行熱萃取後,利用微生物酶對其萃取物進行水解,以獲得青海菜寡醣萃取物(Extraction of Monostroma nitidum oligosaccharides,以下簡稱MO);最後,將該臺灣鯛發酵凍乾萃取物(EFT)與青海菜寡醣萃取物(MO)依一預定重量百分比(如:1:1或1:2)複合成為一複合材料,該複合材料經一系列實驗及分析已證實,不僅其中γ-胺基丁酸(γ-aminobutyric acid,簡稱GABA)的含量遠高過EFT與MO本身的GABA含量,且經膠體過濾層析分析,其內活性胜肽分子量分佈範圍約為90~2030Da,可被劃分成6個波峰區域(A~F),且以分子量為590-720Da的劃分區域C對ACE的有效抑制百分比(inhibitory efficiency ratio,IER)為最高(其IER值為178.3%/mg/mL);而該複合材料中游離胺基酸和胜肽含量亦較歷經不同發酵期間所得之EFT本身的游離胺基酸和胜肽含量值為高。甚至,該複合材料抑制ACE活性之IC50值亦遠較EFT與MO本身抑制ACE活性之IC50值為低,顯見EFT與MO複合後所形成之該複合材料將因彼此內活性胜肽間所產生的協同作用,而使得該複合材料具備更佳的ACE抑制效果,據此,該複合材料不僅富含高品質且小分子量的活性胜肽,具備有效抑制血壓上升的作用,尚具有遠較EFT與MO本身更佳的ACE抑制率效,因此,令其得以被選擇作為高品質化粧品或保健食品(用以預防高血壓、心力衰竭、2型糖尿病及腎病等疾病)的主要成份,而能佳惠及確保消費者皮膚及身 體的健康,從而令臺灣鯛冷凍魚片加工後所殘留的優質副產品及臺灣沿海垂手可得的青海菜,能因本發明而獲得更高附加價值的利用。 The main object of the present invention is to provide a method for preparing a health care material by compounding the fermented freeze-dried extract of Taiwan sea bream and the oligosaccharide extract of Qinghai vegetables. The method is a by-product remaining after processing the frozen fish fillet of Tilapia (for Taiwan sea bream frozen fish fillets after processing, such as: residues containing fish bones, fish skin, fish scales and residual meat...) After hot extraction, two lactic acid bacteria are used to extract Perform fermentation and lyophilization for a predetermined period of time to obtain Extraction of Fermented Tilapia (hereinafter referred to as EFT); after hot extraction of Qinghai vegetables (Monostroma nitidum), extract it with microbial enzymes Hydrolysis to obtain Extract of Monostroma nitidum oligosaccharides (hereinafter referred to as MO); finally, the Taiwan sea bream fermented freeze-dried extract (EFT) and Qinghai vegetable oligosaccharide extract (MO) are scheduled The weight percentage (such as: 1:1 or 1:2) is compounded into a composite material. The composite material has been confirmed by a series of experiments and analysis, not only the content of γ-aminobutyric acid (GABA) Much higher than the GABA content of EFT and MO itself, and analyzed by colloidal filtration chromatography, the molecular weight distribution of active peptides is about 90~2030Da, which can be divided into 6 peak areas (A~F), and the molecular weight The divided area C of 590-720Da has the highest effective inhibition percentage (IER) of ACE (the IER value is 178.3%/mg/mL); and the content of free amino acids and peptides in the composite material is also The free amino acid and peptide content values of EFT itself obtained through different fermentation periods are higher. The composite material is formed even after the composite material 50 inhibition value IC ACE activity is also much higher than the activity of the EFT IC ACE inhibition MO 50 itself is low, the apparent EFT MO compound will vary within each other between the activity of the peptide The resulting synergistic effect makes the composite material have better ACE inhibitory effect. According to this, the composite material is not only rich in high-quality and small molecular weight active peptides, but also has the effect of effectively suppressing the rise of blood pressure. It has better ACE inhibition efficiency than MO itself, so it can be selected as the main component of high-quality cosmetics or health foods (to prevent diseases such as hypertension, heart failure, type 2 diabetes, and kidney disease). Benefiting to ensure the health of consumers' skin and body, the high-quality by-products left after processing of Taiwan sea bream frozen fish fillets and Qinghai vegetables easily available along the coast of Taiwan can be utilized for higher added value due to the present invention.

為便 貴審查委員能對本發明之目的、技術特徵及其功效,做更進一步之認識與瞭解,茲舉實施例配合圖式,詳細說明如下: In order for your reviewing committee to have a better understanding and understanding of the purpose, technical features and efficacy of the present invention, the following examples and drawings are used to explain in detail:

〔習知〕 〔Knowledge〕

None

〔本發明〕 〔this invention〕

200~207‧‧‧步驟 200~207‧‧‧step

301~305、401~405‧‧‧步驟 301~305, 401~405‧‧‧ steps

第1圖係肽由胺基酸之胺基(-NH2)與羧基(-COOH)脫水縮合而形成肽鍵後所形成之鏈狀分子結構示意圖;第2圖係本發明由臺灣鯛加工後副產品經發酵及培養萃取出臺灣鯛發酵凍乾萃取物之製造流程示意圖;第3圖係本發明自青海菜中萃取出青海菜寡醣之製造流程示意圖;第4圖係本發明之臺灣鯛發酵凍乾萃取物的蛋白質分子量之膠體層析圖譜;第5圖係本發明之青海菜寡醣萃取物MO與複合材料(ETF 30/MO)1/1、(ETF 30/MO)1/2的蛋白質分子量之膠體層析分析圖譜;及第6圖係本發明之臺灣鯛發酵凍乾萃取物EFT之膠體層析劃分物C的逆向高效能液相層析圖譜(氰甲烷線性梯度濃度0-100%)。 Figure 1 is a schematic diagram of the chain molecular structure of the peptide formed by the dehydration and condensation of the amino group (-NH2) of the amino acid and the carboxyl group (-COOH) to form a peptide bond; Figure 2 is the by-product of the invention after processing by Taiwan sea bream A schematic diagram of the manufacturing process for extracting the fermented freeze-dried extract of Taiwan sea bream by fermentation and cultivation; FIG. 3 is a schematic diagram of the manufacturing process for extracting oligosaccharides from Qinghai vegetables of the present invention; FIG. 4 is a fermented frozen sea bream of the present invention Colloid chromatogram of protein molecular weight of the dry extract; Figure 5 is the protein of the oligosaccharide extract MO and composite materials (ETF 30/MO) 1/1, (ETF 30/MO) 1/2 of the invention Colloid chromatography analysis spectrum of molecular weight; and Figure 6 is the reverse high-performance liquid chromatography spectrum of the colloidal chromatography partition C of the Taiwan sea bream fermentation lyophilized extract EFT (linear gradient concentration of cyanogen methane 0-100%) ).

有鑒於多年來相關胜肽產品業界始終汲汲營營不斷地探索及研究如何在眾多膳食蛋白質(dietary protein)中挑選出一種價廉物美的優質膳食蛋白質?並據以製作出優質的「活性胜肽」材料,發明人基於多年來從事水產食材的養殖、分析及研究所養成之豐富實務經驗,乃思及利用臺灣鯛(Tilapia)加工後所遺留下來之價廉物美且品質優異的副產品(即,臺灣 鯛冷凍魚片加工後之殘留物,如:含有魚骨、魚皮、魚鱗及殘肉...等物質的殘留物)中之優質膳食蛋白質,及利用臺灣沿海垂手可得的青海菜,分別據以製作出優質且價格合宜的「活性胜肽」及「青海菜寡醣萃取物」,進而據以複合出具備更佳保健效果及作用的「活性胜肽」複合材料,從而能佳惠對優質「活性胜肽」產品有迫切需求的普羅大眾。 In view of the fact that the related peptide product industry has been continuously exploring and studying how to select a cheap, high-quality dietary protein from many dietary proteins over the years. Based on the production of high-quality "active peptide" materials, the inventor is based on the rich practical experience in the cultivation, analysis and research of aquatic food ingredients for many years, thinking about what is left after processing with Taiwan sea bream (Tilapia) High-quality dietary protein in low-cost, high-quality by-products (ie, residues from processing of Taiwan sea bream frozen fish fillets, such as residues containing fish bones, fish skin, fish scales and residual meat...), And using Qinghai vegetables that are readily available along the coast of Taiwan, to produce high-quality and affordable "active peptides" and "Qinghai vegetables oligosaccharide extracts", respectively, and to synthesize "active wins" with better health effects and functions. "Peptide" composite materials, so that Canon can benefit the general public who have an urgent need for high-quality "active peptide" products.

按,在民國七十年左右,人們能在菜市場買得到的廉價魚貨,幾乎全是被稱為「福壽魚」的「混種吳郭魚」,甚至,在魚業養殖技術不斷地進步下,八十年代後,市面上已有全雄性的「單性吳郭魚」出現。早年,由於「吳郭魚」的養殖方式係採用農漁牧綜合的有機經營方式,造成「吳郭魚」食取「豬糞」、「雞糞」及「鴨糞」等的負面印象,始終深植一般消費者腦海中,嗣,在海水養殖技術不斷提升及遠洋魚業不斷進步與擴張的環境下,其他替代魚種與進口魚種等乃不斷地增加,且隨著經濟條件的逐漸好轉,消費者對於水產品的需求也日趨求新求變,導致「吳郭魚」在國內消費者心目中已逐漸被列為低價位的下等魚種,同時,在過去漁政單位未特別注意與輔導的情況下,自然使得「吳郭魚」的市場價位長期處於低落且欲振乏力的地位。 According to the press, in the seventy years of the Republic of China, almost all of the cheap fish goods that people could buy in the vegetable market were "mixed Wu Guo fish" called "fushou fish". Even, the fish farming technology continued Under the progress, after the 1980s, the all-male "sexual Wu Guoyu" has appeared on the market. In the early years, due to the organic management of agriculture, fishery and animal husbandry, the cultivation method of "Wu Guoyu" caused the negative impression of "Wu Guoyu" eating and drinking "pig dung", "chicken dung" and "duck dung". Deeply planted in the minds of ordinary consumers, under the circumstances of the continuous improvement of marine aquaculture technology and the continuous progress and expansion of the ocean fish industry, other alternative fish species and imported fish species are constantly increasing, and with the gradual improvement of economic conditions Consumers’ demand for aquatic products is also changing day by day. As a result, "Wu Guoyu" has gradually been listed as a low-priced inferior fish species in the minds of domestic consumers. In the case of attention and counseling, the market price of "Wu Guoyu" has naturally been in a low and weak position for a long time.

所幸在後續養殖業界繼任者的長期辛勤努力研究、開發及推廣下,始逐步打開國際市場,使得臺灣所養殖出的「吳郭魚」廣為各方所接受。從此,臺灣養殖業界為了建立臺灣自身之優質漁業品牌,不僅在種苗繁殖技術、養成技術、飼料配方、加工技術等各方面均負出極大的資金及努力,且在歷經諸多困境,逐一突破改良後,終於成功地培育出更優質的「吳郭魚」,並在將其正式命名為「臺灣鯛」(Tilapia)後,遂以「臺灣鯛」 之名進軍國際市場,期「臺灣鯛」能創造出臺灣漁業養殖的另一個新契機。近年來,幾經各方面持續不斷地努力改良及推廣下,優質化的「臺灣鯛」品種,已逐漸成為臺灣水產品的主要代表品項,不但廣受國內消費者肯定,在對日本、美國、韓國等地的外銷市場方面,也屢創佳績。目前,「臺灣鯛」的產地在臺灣之南部地區係以嘉義縣為主〈中、北部地區雖亦有少部分養殖魚塭蓄養,但是,全台的養殖產量仍是以雲嘉南地區為最多〉。「臺灣鯛」之所以能廣受國內外消費者的青睞,不僅與臺灣鯛養殖業界豐富的養殖經驗及優異的養殖技術所培養出的高品質肉質有關,亦與臺灣鯛冷凍魚片加工業界優異且嚴謹的加工流程有著密不可分的關係,凡此種種均令其所據以製成的臺灣鯛冷凍魚片能廣獲國內外消費者的好評。 Fortunately, with the long-term hard work of subsequent successors in the breeding industry, research, development and promotion, it gradually opened up the international market, making the "Wu Guoyu" farmed in Taiwan widely accepted by all parties. Since then, in order to establish Taiwan's own high-quality fishery brand, Taiwan's aquaculture industry has not only invested huge funds and efforts in seedling breeding technology, cultivation technology, feed formulation, processing technology and other aspects, but also experienced many difficulties and made breakthroughs one after another. , And finally succeeded in cultivating better quality "Wu Guoyu", and after officially named it as "Taiwan Snapper" (Tilapia), then entered the international market under the name of "Taiwan Snapper". Another new opportunity for Taiwan's fish farming. In recent years, after continuous efforts to improve and promote various aspects, the high-quality "Taiwan Snapper" variety has gradually become the main representative item of Taiwan’s aquatic products, not only widely recognized by domestic consumers, but also South Korea and other places have also repeatedly achieved good results in the export market. At present, the production area of "Taiwan Snapper" is mainly in Chiayi County in the southern region of Taiwan. Although there are a small number of farmed fish farms in the central and northern regions, the production output of Taiwan is still the largest in Yunnan and Jianan. 〉. The reason why "Taiwan sea bream" is widely favored by consumers at home and abroad is not only related to the high-quality meat quality cultivated by the rich farming experience and excellent farming technology of the Taiwan sea bream farming industry, but also to the excellence of the Taiwan sea bream frozen fish fillet processing industry. And the rigorous processing process has an inseparable relationship, all of which makes the Taiwan sea bream frozen fish fillet based on it can be widely praised by domestic and foreign consumers.

茲就臺灣鯛的整個產業觀之,臺灣鯛養殖業界必需透過多年來所養成的優異養殖技術與豐富養殖經驗,加上多年來對臺灣鯛養殖辛勤與細心付出的血汗照顧,始能養殖出及收獲到如此高品質肉質的臺灣鯛,最後,尚必需在臺灣鯛加工業界優異、嚴謹且複雜的加工作業搭配下,始能被製作成高品質的臺灣鯛冷凍魚片,據此,臺灣鯛冷凍魚片加工後所殘餘的大量且高品質的副產品(如:魚骨、魚皮及被修整下來之碎肉...等),若僅能被回收利用,製成價格低廉的飼料或肥料,其在價值上的利用率顯然偏低,除殊為可惜之外,亦頗有嚴重辜負臺灣養殖及加工業界多年來養成的優異養殖及加工技術與經驗及辛勤血汗付出各項努力之遺憾。 With regard to the entire industry of Taiwan seabream, Taiwan seabream aquaculture industry must be able to breed and develop through years of excellent farming techniques and rich farming experience, plus years of hard work and careful care of Taiwan sea bream farming. After harvesting such high-quality meaty Taiwan sea bream, in the end, it must be combined with the excellent, rigorous and complex processing operations of the Taiwan sea bream processing industry before it can be made into high-quality Taiwan sea bream frozen fish fillets. A large amount of high-quality by-products (such as fish bones, fish skins, and minced meat that has been trimmed... etc.) remaining after the processing of fish fillets can only be recycled to make inexpensive feed or fertilizer, Its utilization rate in value is obviously low. In addition to being a pity, it also quite lives up to the regret of the excellent breeding and processing technology and experience developed by Taiwan's breeding and processing industry for many years and the hard work of hard work.

有鑒於此,發明人乃思及有效利用臺灣鯛加工後所殘留之優質副產品(即,臺灣鯛冷凍魚片加工後之殘留物,含有魚骨、魚皮、魚鱗及殘肉...等物質之殘留物),據以培養及製造出高品質之活性胜肽,而令臺 灣鯛冷凍魚片加工後所殘留之優質副產品能獲得更高附加價值的利用;本發明係一種由臺灣鯛發酵凍乾萃取物與青海菜寡醣萃取物複合成保健材料之製法,該製法係先將臺灣鯛(Tilapia)冷凍魚片加工後殘留之副產品(為臺灣鯛冷凍魚片加工後之殘留物,如:含有魚骨、魚皮、魚鱗及殘肉...等物質的殘留物)利用熱萃取方式進行萃取後,使用兩種乳酸菌分別對其萃取物執行一預定期間的發酵及凍乾處理,以獲得富含優質「活性胜肽」的臺灣鯛發酵凍乾萃取物(Extraction of fermented Tilapia,以下簡稱EFT);其次,針對青海菜(Monostroma nitidum)進行熱萃取後,利用微生物酶對其萃取物進行水解,以獲得青海菜寡醣萃取物(Extraction of Monostroma nitidum oligosaccharides,以下簡稱MO);最後,將該臺灣鯛發酵凍乾萃取物(EFT)與青海菜寡醣萃取物(MO)依一預定重量百分比(如:1:1或1:2)複合成為一複合材料。其中,請參閱第2圖所示,該臺灣鯛發酵凍乾萃取物(EFT)的製程,係包括下列步驟(按,以下各製程的步驟均係發明人在歷經過多次製程實作,反覆分析及調整各製程步驟中的細節及條件後所歸納出的最佳步驟、數據及條件,因此,為了簡化說明起見,本發明在後續的描述中僅以最佳步驟、數據及條件為例,說明後續製程,惟,本發明之製法在實際施作時,不僅不挶限於此,其步驟、數據及條件,亦均能依實際需要,予以微調,只要其數據及條件的微調範圍在以下所列數據及條件的±5%範圍內,仍應能達成本發明之主要目的,而獲得所需之EFT、MO及複合材料,亦為本發明在此欲主張保護的權利範圍;同時,本發明製程中所使用的原料亦不挶限於臺灣鯛冷凍魚片加工後之殘留物,亦能依實際的需要(如:在臺灣鯛生產過剩或滯銷期間),使用臺灣鯛全魚或其魚片,予以取代,亦為本發明在此 欲主張保護的權利範圍,合先陳明。首先,復請參閱第2圖所示,本發明據以製作該臺灣鯛發酵凍乾萃取物(EFT)之方法,包括下列步驟: In view of this, the inventors thought about the effective use of high-quality by-products left after processing of Taiwan sea bream (ie, the residues of Taiwan sea bream frozen fish fillet processing, containing fish bones, fish skin, fish scales and residual meat...etc. Residues), based on the cultivation and production of high-quality active peptides, and the high-quality by-products remaining after processing of Taiwan sea bream frozen fish fillets can be used for higher added value; the present invention is a fermented frozen sea bream from Taiwan The dry extract and the oligosaccharide extract of Qinghai vegetable are compounded into a health-care material. The method is to first process by-products remaining after the processing of Taiwanese sea bream (Tilapia) frozen fish fillet (the residue after processing of Taiwan sea bream frozen fish fillet, such as: (Residues containing fish bones, fish skin, fish scales and residual meat...) After hot extraction, the two lactic acid bacteria are used to perform fermentation and lyophilization on their extracts for a predetermined period of time to obtain Extract of fermented Tilapia (hereinafter referred to as EFT) rich in high-quality "active peptides"; secondly, after hot extraction of Qinghai vegetables (Monostroma nitidum), the extract is hydrolyzed by microbial enzymes To obtain Extraction of Monostroma nitidum oligosaccharides (hereinafter referred to as MO); finally, the Taiwan sea bream fermented freeze-dried extract (EFT) and Qinghai vegetable oligosaccharide extract (MO) according to a predetermined weight percentage (For example: 1:1 or 1:2) The composite becomes a composite material. Among them, as shown in Figure 2, the process of fermentation and freeze-drying extract (EFT) of Taiwan sea bream includes the following steps (press, the steps of the following processes are implemented by the inventor after multiple processes and repeated analysis And the best steps, data and conditions summarized after adjusting the details and conditions in each process step. Therefore, in order to simplify the description, the present invention uses only the best steps, data and conditions as examples in the subsequent description. Explain the subsequent process, but the actual implementation of the method of the present invention is not limited to this, its steps, data and conditions can also be fine-tuned according to actual needs, as long as the fine-tuning range of its data and conditions is as follows Within the range of ±5% of the listed data and conditions, it should still be able to achieve the main purpose of the invention, and obtaining the required EFT, MO and composite materials is also the scope of the right of the invention to claim protection; at the same time, the invention The raw materials used in the process are not limited to the residues of Taiwan sea bream frozen fish fillet processing, but can also use Taiwan sea bream whole fish or their fillets according to actual needs (such as during the overproduction or unsalable production of Taiwan sea bream). The replacement is also the scope of the rights claimed by the present invention here, and it is stated first. First of all, please refer to FIG. 2 for the method of preparing the fermented freeze-dried extract (EFT) of the Taiwan sea bream. , Including the following steps:

(200)熱萃取處理:將臺灣鯛加工後殘留之該副產品均勻絞碎後,取2公斤(kg)加入10公升(L)的水,形成一「副產品碎屑混合液」,再以大火烹煮該「混合液」,俟沸騰後轉中火,繼續烹煮至該「混合液」僅剩5公升後,以濾網對該「混合液」進行過濾,即能獲得「澄清液」與「魚骨渣」;其中,繼續烹煮該「澄清液」直到僅剩2公升;「魚骨渣」則是在加入5公升的水,形成一「魚骨渣混合液」後,以大火烹煮該「魚骨渣混合液」,俟沸騰後轉中火,繼續烹煮至僅剩1公升後,以濾網對該「魚骨渣混合液」進行過濾;最後,將其濾液和前者混合後,即獲得「粗萃取液」,且將該「粗萃取液」凍結在攝氏-20度,24小時後,對該凍結的「粗萃取液」進行表面除油後,再對其進行冷凍乾燥,以形成凍乾的「魚粗萃粉末」。 (200) Hot extraction treatment: After the by-products of Taiwan sea bream are minced evenly, take 2 kilograms (kg) and add 10 liters (L) of water to form a "by-product debris mixture", then cook on high heat Cook the "mixed liquid", turn it to medium heat as soon as it boils, and continue to cook until the "mixed liquid" has only 5 liters left, filter the "mixed liquid" with a filter to obtain the "clarified liquid" and "" "Fish bone residue"; where, continue to cook the "clear liquid" until only 2 liters remain; "fish bone residue" is to add 5 liters of water to form a "fish bone residue mixed liquid" and cook on high heat The "fish bone residue mixture", once boiled, turn to medium heat, and continue to cook until only 1 liter is left, then filter the "fish bone residue mixture" with a filter screen; finally, after mixing the filtrate and the former , The "crude extract" is obtained, and the "crude extract" is frozen at -20 degrees Celsius. After 24 hours, the frozen "crude extract" is degreased on the surface, and then freeze-dried. In order to form freeze-dried "fish crude extract powder".

(201)第一次滅菌處理:將重量百分比為2%之該「魚粗萃粉末」(如:120公克)及重量百分比為1%之葡萄糖(如:60公克),分別加入至一塑膠桶內20公升的純水中後,適當搖晃該塑膠桶,俟三者均勻混合後,即蓋上該塑膠桶之桶蓋,且將該塑膠桶放入至一滅菌釜中,以攝氏121度,進行30分鐘的滅菌處理,完成後待冷卻至室溫攝氏25度,即形成一「魚粗萃粉末葡萄糖混合液」。 (201) The first sterilization treatment: add 2% by weight of the "fish crude extract powder" (eg: 120 g) and 1% by weight of glucose (eg: 60 g) to a plastic bucket After 20 liters of pure water, shake the plastic bucket properly. Once the three are evenly mixed, cover the plastic bucket and put the plastic bucket into a sterilization kettle at 121 degrees Celsius. After 30 minutes of sterilization treatment, after completion, it is cooled to room temperature 25 degrees Celsius to form a "fish crude extract powder glucose mixed solution".

(202)發酵處理:利用接種環以無菌操作方式,分別自保存在攝氏-80度凍藏櫃中的乳酸菌Enterococcus faecalis(BCRC 14046)與Lactobacillus rhamnosus(BCRC 10940)之保存凍管,勾取一環,且三區劃線在MRSA培養基(MRS arga是培養及計數乳酸桿菌的培養基)上,在攝氏37 度的環境下,培養24小時(稱為第一次活化);嗣,再以接種環勾取一獨立分離菌落,且三區劃線在新的MA培養基上,在攝氏37度的環境下,培養24小時(稱為第二次活化);接著,再以接種環勾取第二次活化之獨立分離菌落分別接種至60毫升之MRSB培養基中,以手搖晃均勻後,置入直立式振盪培養箱中,在攝氏37度的環境下,培養至菌落密度OD 600nm等於0.8~1.0時,以無菌操作方式,利用電動吸管(Pipet-Aid)分別吸取重量百分比為1%(60mL)之BCRC14046及BCRC10940乳酸菌,且將其加入至前述塑膠桶內已冷卻的20公升「魚粗萃粉末葡萄糖混合液」中,在攝氏37度的環境下,分別發酵0、10、20及30小時後,即形成「魚粗萃粉末葡萄糖混合發酵液」。 (202) Fermentation treatment: use the inoculation ring to aseptically operate from the frozen tubes of the lactic acid bacteria Enterococcus faecalis (BCRC 14046) and Lactobacillus rhamnosus (BCRC 10940) stored in the -80 degrees Celsius freezer, and pick a ring. And the three-division line is on MRSA medium (MRS arga is the medium for culturing and counting Lactobacillus), cultured at 37 degrees Celsius for 24 hours (referred to as the first activation); then, take one with the inoculation ring Isolate the colonies independently, and divide the three areas on the new MA medium at 37 degrees Celsius for 24 hours (referred to as the second activation); then, use the inoculation loop to capture the independent isolation of the second activation Inoculate the colonies in 60 ml of MRSB medium, shake them evenly by hand, and place them in an upright shaking incubator. Cultivate them to a colony density of OD 600nm equal to 0.8~1.0 under the environment of 37 degrees Celsius. Draw up 1% (60mL) of BCRC14046 and BCRC10940 lactic acid bacteria by electric pipette (Pipet-Aid), and add it to the cooled 20-liter "fish crude powdered glucose mixed solution" in the aforementioned plastic bucket, Under the environment of 37 degrees Celsius, after fermentation for 0, 10, 20 and 30 hours, a "fish crude extract powder glucose mixed fermentation broth" is formed.

(203)第二次滅菌處理:將前述含「魚粗萃粉末葡萄糖混合發酵液」的塑膠桶放入至一殺菌釜中,以攝氏121度進行30分鐘的滅菌處理後,停止發酵,即獲得已完成發酵的「魚粗萃粉末葡萄糖混合發酵液」,且依發酵時間0、10、20及30小時,分別編號為EFT0、EFT10、EFT20及EFT30。 (203) The second sterilization treatment: put the aforementioned plastic bucket containing "fish crude extract powder glucose mixed fermentation broth" into a sterilization kettle, sterilize it at 121 degrees Celsius for 30 minutes, stop the fermentation, and obtain The "Fish Crude Extract Powder and Glucose Mixed Fermentation Broth" that has been fermented and is numbered EFT0, EFT10, EFT20 and EFT30 according to the fermentation time of 0, 10, 20 and 30 hours, respectively.

(204)離心分離處理:以無菌操作方式,將各該完成發酵的「魚粗萃粉末葡萄糖混合發酵液」,分批裝入至已滅菌之離心管中約7分滿(如:300毫升),再將各該離心管放入至已預冷至攝氏4度的離心機中,且使該離心機以14000 x g的速度離心運轉30分鐘,即能獲取各該離心管中之「上清液」部分。 (204) Centrifugal separation process: Aseptic operation, each of the "fermented fish crude powdered glucose mixed fermentation broth" that has been completely fermented is filled in batches into a sterilized centrifuge tube about 7 minutes full (eg: 300 ml) , Then put each centrifuge tube into a centrifuge that has been pre-cooled to 4 degrees Celsius, and let the centrifuge run at 14000 xg for 30 minutes to obtain the "supernatant" in each centrifuge tube. "section.

(205)抽氣過濾處理:將已滅菌之一抽氣過濾裝置與2公升之一血清瓶組裝成為一體,對自各該離心管所獲取之「上清液」部分進行 過濾,其中,為了預防抽氣過濾裝置內0.45μm的濾膜在過濾時無法順利進行或被堵塞,會先將該「魚粗萃粉末葡萄糖混合發酵液」離心過後之該「上清液」倒入至已放上6.0μm濾膜之抽氣過濾裝置進行過濾,再接續地將該「上清液」依序以1.0μm及0.5μm濾膜分別過濾;最後,始以0.45μm濾膜透過該抽氣過濾裝置進行過濾,在此需特別聲明者,為確保本發明的製程品質,以上的過濾作業均應盡量保持在無菌操作方式下進行。 (205) Suction filtration treatment: Assemble a sterilized suction filtration device and a 2 liter serum bottle into one body, and filter the "supernatant" part obtained from each centrifuge tube. Among them, in order to prevent suction The 0.45μm filter membrane in the air filtration device cannot be smoothly carried out or is blocked during filtration. The "supernatant" after centrifuging the "fish crude extract powder glucose mixed fermentation broth" will be poured into 6.0μm. The suction filtration device of the filter membrane is used to filter, and then the "supernatant" is successively filtered through the 1.0μm and 0.5μm filter membranes; finally, the 0.45μm filter membrane is used to filter through the suction filter device. It should be specially stated here that in order to ensure the quality of the process of the present invention, the above filtration operations should be carried out under aseptic operation as much as possible.

(206)舖盤凍乾處理:將經過前述抽氣過濾裝置完成過濾的該「上清液」倒置且平舖在一不鏽鋼凍乾盤上,每片凍乾盤上約能鋪上700~800毫升的該「上清液」,多餘的發酵液須分裝至2公升的血清瓶中,且放置入一殺菌釜內,在攝氏121度的環境下,進行20分鐘的滅菌處理後,待冷卻至約攝氏25度的室溫,即能將其存放至攝氏4度的冰箱內保存,待下次再進行抽氣過濾及舖盤凍乾。已舖好在各該不鏽鋼凍乾盤上之該上清液,則分別依序被放入至一凍乾機中,在攝氏-80度的環境下,進行約3天的凍乾處理。 (206) Plating freeze-drying treatment: the "supernatant" filtered by the aforementioned air filtration device is inverted and flattened on a stainless steel freeze-drying tray, each piece of freeze-drying tray can be covered with about 700~800 Ml of this "supernatant", the excess fermentation broth must be dispensed into a 2 liter serum bottle, and placed in a sterilization kettle, under the environment of 121 degrees Celsius, after 20 minutes of sterilization, wait for cooling It can be stored in a refrigerator at 4 degrees Celsius to a room temperature of about 25 degrees Celsius. It will be filtered by air suction and freeze-dried after the next time. The supernatants that have been spread out on each of the stainless steel freeze-drying plates are sequentially put into a freeze-drying machine and subjected to freeze-drying treatment for about 3 days in an environment of -80 degrees Celsius.

(207)獲取臺灣鯛發酵凍乾萃取物:俟完成前述凍乾處理後,以已完成滅菌的藥杓,將經凍乾而形成粉末狀的臺灣鯛發酵凍乾萃取物(Extraction of fermented Tilapia,簡稱EFT)迅速地刮入至已知重量的離心管中,以避免吸濕,俟經電子天平秤重,並分別依發酵期間0、10、20及30小時,標示為EFT0、EFT10、EFT20及EFT30等樣品後,將各該離心管儲存至一乾燥箱內,靜待後續實驗、分析及使用。 (207) Obtaining the fermented freeze-dried extract of Taiwan sea bream: After completing the aforementioned freeze-drying process, the sterilized medicine scoop is used to freeze-dry and form a powdered Taiwan sea bream fermented freeze-dried extract (Extraction of fermented Tilapia, (Referred to as EFT) quickly scraped into a centrifuge tube of known weight to avoid moisture absorption, weighed by an electronic balance, and marked as EFT0, EFT10, EFT20 and EFT0 according to 0, 10, 20 and 30 hours of fermentation period, respectively After EFT30 and other samples, store each centrifuge tube in a dry box and wait for subsequent experiments, analysis and use.

另,發明人基於多年來對臺灣沿海藻類的研究,深知每年十二月至翌年四月盛產在臺灣、日本、韓國及中國礁石岩岸地區,藻體呈黃 綠色或蛋黃色且學名為「Monostroma latissimum」的「青海菜」係礁膜屬的一種海藻,臺灣每年的產量約76公噸,主要係產自澎湖,除可供作鮮食外,亦能被製成加工食品,如:海苔片、海苔醬、海苔酥、海苔花生等,且其萃取物中尚包含許多特殊成分,如:硫酸多醣或酸性多醣、蛋白質、色素等,不僅能抑制過氧化物及自由基的形成(Mekideche and Briand 1994參照),可做為提升免疫力及抗癌的活性物質,亦具有降低膽固醇的作用及效果(Maeda et al.,1991參照),此外,尚能用以提煉出各種藻膠,如:洋菜、褐藻酸、角叉藻聚醣等,以利用其特殊的凝膠性、粘稠性及乳化性,而廣泛地被應用在食品工業。據此,發明人乃思及自該「青海菜」中萃取出「青海菜寡醣」,且將其添加至該臺灣鯛發酵凍乾萃取物(EFT)中,以探討其成份及凝膠性對該臺灣鯛發酵凍乾萃取物(EFT)中活性胜肽及其生化特性的影響,以期能增加「青海菜」的應用領域,從而能有效提高「青海菜」的利用價值。 In addition, based on many years of research on Taiwan's coastal algae, the inventor knows that the algae body is yellow-green or egg yellow and the scientific name is abundant in the reef rocky areas of Taiwan, Japan, South Korea and China every December to April of the following year. "Monostroma latissimum" is a seaweed of the "Qinghaicai" family of reef membranes. Taiwan's annual output is about 76 metric tons. It is mainly produced from Penghu. In addition to being available for fresh food, it can also be made into processed foods, such as seaweed flake , Seaweed sauce, seaweed crisp, seaweed peanuts, etc., and the extract still contains many special ingredients, such as: sulfated polysaccharides or acidic polysaccharides, proteins, pigments, etc., not only can inhibit the formation of peroxides and free radicals (Mekideche and Briand 1994 reference), which can be used as an active substance for improving immunity and anti-cancer, and also has a cholesterol-lowering effect and effect (Maeda et al., 1991 reference). In addition, it can still be used to extract various algae, such as: Vegetables, alginic acid, carrageenan, etc., are widely used in the food industry to take advantage of their special gelation, viscosity and emulsification. Based on this, the inventor thought about extracting "Qinghai Vegetable Oligosaccharide" from the "Qinghai Vegetable" and adding it to the Taiwan Sea Bream Fermented Freeze-Dried Extract (EFT) to explore its composition and gelability The impact on the active peptide and its biochemical properties in the fermented freeze-dried extract (EFT) of Taiwan sea bream is expected to increase the application field of "Qinghai vegetables" and thus effectively increase the use value of "Qinghai vegetables".

在本發明中,請參閱第3圖所示,自該「青海菜」中萃取出青海菜寡醣的製法,包括下列步驟: In the present invention, referring to FIG. 3, the method for extracting Qinghai vegetable oligosaccharide from the "Qinghai vegetable" includes the following steps:

(301)製備「MMB培養基」:首先,預先準備經過一次純水潤洗過的2公升容量之三角錐形瓶2個;嗣,分別於各該三角錐形瓶內配製具有下表一所示成份的「MMB培養基」1.3公升,該「MMB培養基」中之熱萃液係指「青海菜熱萃液」,Algal powder係指「青海菜乾藻粉」,並以雙層鋁箔紙封住各該三角錐形瓶之瓶口,且於磁加熱板上加熱攪拌至二次沸騰後,置入一殺菌釜,在攝氏121度的環境下,執行15分鐘的滅菌處理,俟完成該滅菌處理後,待冷卻至室溫攝氏25度時,自該三角錐 形瓶內取樣10毫升。 (301) Preparation of "MMB medium": First, prepare two 2-liter triangular conical flasks with a volume of pure water in advance; then, prepare the three conical flasks with the following table 1 The composition of the "MMB medium" is 1.3 liters. The hot extract in the "MMB medium" means "Qinghai vegetable hot extract", Algal powder means "Qinghai vegetable dried algae powder", and each layer is sealed with double aluminum foil The mouth of the triangular conical bottle is heated and stirred on the magnetic heating plate until it is boiled for a second time, and then placed in a sterilization kettle. Under the environment of 121 degrees Celsius, the sterilization process is performed for 15 minutes. After the sterilization process is completed After cooling to 25 degrees Celsius at room temperature, sample 10 ml from the triangular conical flask.

Figure 107128857-A0101-12-0018-13
Figure 107128857-A0101-12-0018-13

(302)接種「微生物酶」:利用接種環以無菌操作方式,自保存在攝氏-80度凍藏櫃中的P.vesicularis MA103與A.salmonicida MAEF108「微生物酶」之保存凍管,分別勾取一環,且三區劃線在MA培養基上,在攝氏26度的環境下,培養24小時(第一次活化);嗣,再以接種環勾取一獨立分離菌落且三區劃線在新的MA培養基上,在攝氏26度的環境下,培養24小時(二次活化);接著,再以接種環勾取二次活化之獨立分離菌落分別接種至13毫升之MB培養基中,以手輕微搖晃均勻後,置入直立式振盪培養箱中,在攝氏26度的環境下,以90rpm的速度振盪培養,俟培養至菌落密度OD 600nm等於0.8~1.0時,以無菌操作方式,利用電動吸管(Pipet-Aid)分別吸取重量百分比為1%之MA103及MAEF108(如:13毫升)微生物酶,且分別將其加入至2公升容量之各該三角錐形瓶內已冷卻的該MMB培養基中,並在各該三角錐形瓶之瓶口套上適當大小的矽質瓶塞。 (302) Inoculation of "microbial enzymes": use the inoculation loop to aseptically operate and save the frozen tubes of P.vesicularis MA103 and A. salmonicida MAEF108 "microbial enzymes" stored in the -80 degrees Celsius freezer, respectively. One ring, and the three-zone line on the MA medium, cultured at 26 degrees Celsius for 24 hours (the first activation); then, use the inoculation ring to pick an independent colony and the three-zone line on the new MA medium Above, incubate for 24 hours at a temperature of 26 degrees Celsius (secondary activation); then, inoculate the isolated secondary isolated colonies with secondary activation by inoculation loop into 13 ml of MB medium, shake gently with your hands evenly , Placed in an upright shaking incubator, shaking culture at a speed of 90rpm under the environment of 26 degrees Celsius, when the culture is reached to a colony density OD 600nm equal to 0.8~1.0, aseptic operation method, using electric pipette (Pipet-Aid ) Draw 1% by weight of MA103 and MAEF108 (eg: 13 ml) microbial enzymes, and add them to the cooled MMB medium in each Erlenmeyer flask with a capacity of 2 liters An appropriately sized silicon stopper is attached to the mouth of the triangular conical bottle.

(303)水解處理產生「粗酵素液」:將2瓶2公升容量之三角錐形瓶置入至一直立式振盪培養箱中,設定在攝氏26度的環境下,以90rpm的速度振盪培養48小時,以誘導MA103及MAEF108等微生物酶能在MMB培養基中產生「粗酵素液」。 (303) Hydrolysis treatment to produce "crude enzyme solution": Place 2 bottles of 2 liter triangular conical flasks into a vertical vertical shaking incubator, set at 26 degrees Celsius, shaking culture at a speed of 90rpm 48 Hour to induce microbial enzymes such as MA103 and MAEF108 to produce "crude enzyme solution" in MMB medium.

(304)離心分離及滅菌處理:以無菌操作方式將MA103及MAEF108在MMB培養基中所誘導產生之「粗酵素液」,分批裝入至已滅菌之離心管中約7分滿(如:300毫升),再將各該離心管依序放入至已預冷至攝氏4度的離心機中,以14000 x g的速度離心運轉30分鐘後,即能利用已滅菌之藥杓及適當的漏斗,自各該離心管獲取「上清液」部分。 (304) Centrifugal separation and sterilization treatment: the "crude enzyme solution" induced by MA103 and MAEF108 in MMB medium in aseptic operation mode is filled in batches into sterilized centrifuge tubes for about 7 minutes (for example: 300 Ml), then put each centrifuge tube into a centrifuge that has been pre-cooled to 4 degrees Celsius, centrifuge at 14000 xg for 30 minutes, then you can use the sterilized medicine dipper and the appropriate funnel, Obtain the "supernatant" portion from each centrifuge tube.

(305)抽氣過濾處理:將已滅菌之一抽氣過濾裝置與2公升之一血清瓶組裝成一體,對自各該離心管所獲取之「上清液」部分進行過濾,其中,為了預防該抽氣過濾裝置內0.45μm的濾膜在過濾時無法順利進行或被堵塞,會先分別將MA103、MAEF108所誘導產生之「粗酵素液」經離心過後的「上清液」部分倒入至已放上1.0μm濾膜之該抽氣過濾裝置,進行過濾,嗣,再接續將液體以0.5μm濾膜進行過濾;最後,始以0.45μm濾膜透過該抽氣過濾裝置,進行過濾,期能過濾掉其中的大分子物質及毒素,並自已完成過濾之由MA103、MAEF108所誘導出的該「粗酵素液」中取樣10毫升。 (305) Suction filtration treatment: Assemble a sterilized suction filtration device and a 2 liter serum bottle into one body, and filter the "supernatant" part obtained from each centrifuge tube. Among them, in order to prevent this The 0.45μm filter membrane in the suction filtration device cannot be smoothly carried out or is blocked during filtration. The "supernatant" part of the "crude enzyme solution" induced by MA103 and MAEF108 after centrifugation will be poured into the Put the suction filter device with a 1.0μm filter membrane to filter, and then continue to filter the liquid with a 0.5μm filter membrane; finally, the 0.45μm filter membrane is used to filter through the suction filter device for filtration. Filter out the macromolecular substances and toxins, and sample 10 ml from the "crude enzyme solution" induced by MA103 and MAEF108.

(401)製備「青海菜熱萃液」:取一20公升容量的塑膠桶,俟洗淨後裝入6公升的一次純水,且在該塑膠桶內加入重量百分比為15%的青海菜(如:0.6kg的濕藻),適當搖晃該塑膠桶,俟青海菜與一次純水均勻混合成「青海菜混合液」後,蓋上塑膠桶之桶蓋,放入至一滅菌釜中,在攝氏121度的環境下,進行30分鐘的滅菌處理,俟完成滅菌處理後,待該塑膠桶冷卻至室溫攝氏25度,即在該塑膠桶內形成了該「青海菜熱萃液」。 (401) Preparation of "Qinghai Vegetable Hot Extract": Take a 20-liter plastic bucket, wash it and fill it with 6 liters of pure water, and add 15% by weight of Qinghai Vegetable to the plastic bucket ( Such as: 0.6kg of wet algae), shake the plastic bucket properly, and mix the Qinghai vegetable with the once pure water to form a "Qinghai vegetable mixed solution", put on the lid of the plastic bucket, and put it into a sterilization kettle. Under the environment of 121 degrees Celsius, sterilize for 30 minutes. Once the sterilization process is completed, wait for the plastic barrel to cool to 25 degrees Celsius at room temperature, and then form the "Qinghai Vegetable Hot Extract" in the plastic barrel.

(402)製備「青海菜待水解液」:將前述所取樣已完成過濾 之由MA103及MAEF108誘導出的該「粗酵素液」,以重量百分比各為10%(如:0.6公升)的比例加入至6公升的該「青海菜熱萃液」中,而形成7.2公升的「青海菜待水解液」。 (402) Preparation of "Qinghai Vegetable Hydrolysate": Add the "crude enzyme liquid" induced by MA103 and MAEF108, which has been sampled and filtered, in a proportion of 10% by weight (eg 0.6 liter) To 6 liters of the "Qinghai Vegetable Hot Extract", 7.2 liters of "Qinghai Vegetable Hydrolysate" was formed.

(403)對「青海菜待水解液」執行水解處理:將7.2公升的該「青海菜待水解液」放置在一迴轉式振盪器上,並在加強固定後設定該迴轉式振盪器以90rpm速度振盪,待MA103及MAEF108所誘導出的該「粗酵素液」與該「青海菜待水解液」中的海藻發生酵素水解反應達48小時後,即形成7.2公升的「青海菜多醣水解液」;嗣,將7.2公升之該「青海菜多醣水解液」依序分裝至1公升之血清瓶中,每瓶約分裝至750毫升即可,俟完成分裝後,將各該血清瓶放入至一殺菌釜中,在攝氏121度的環境下,執行15分鐘的滅菌處理,並在終止酵素水解反應後,對該「青海菜多醣水解液」進行取樣。 (403) Perform hydrolysis treatment on "Qinghai Vegetable Hydrolysate": place 7.2 liters of "Qinghai Vegetable Hydrolysate" on a rotary oscillator, and set the rotary oscillator at a speed of 90 rpm after strengthening and fixing After shaking, after the enzyme hydrolysis reaction between the "crude enzyme solution" induced by MA103 and MAEF108 and the seaweed in the "Qinghai vegetable hydrolysate" has occurred for 48 hours, 7.2 liters of "Qinghai vegetable polysaccharide hydrolysate" will be formed; Then, dispense 7.2 liters of the "Qinghai Vegetable Polysaccharide Hydrolysate" into 1 liter serum bottles in sequence, each bottle can be divided into approximately 750 ml, and after the completion of the packaging, put each serum bottle into In a sterilization kettle, perform sterilization for 15 minutes in an environment of 121 degrees Celsius, and after stopping the enzyme hydrolysis reaction, sample the "Qinghai Vegetable Polysaccharide Hydrolysate".

(404)舖盤凍乾處理:將所取樣的該「青海菜多醣水解液」以無菌操作方式,倒入至已滅菌且包覆了二層鋁箔(並貼上進口耐凍膠帶,以避免鋁箔縫隙滲入空氣)之一不鏽鋼凍乾盤中,每盤約可倒入700~800毫升之該「青海菜多醣水解液」,且將各該不鏽鋼凍乾盤分別放入至一凍乾機中,在攝氏-60度的環境下,執行3天的凍乾處理。 (404) Plate freeze-drying treatment: Pour the sampled "Qinghai Vegetable Polysaccharide Hydrolysate" into the sterilized and covered with two layers of aluminum foil aseptically (and paste imported freeze-resistant tape to avoid gaps in the aluminum foil Infiltrate the air) one of the stainless steel freeze-drying trays, each of which can be filled with about 700-800 ml of the "Qinghai Vegetable Polysaccharide Hydrolysate", and put each of the stainless steel freeze-drying trays into a freeze dryer, in Perform lyophilization for 3 days at -60 degrees Celsius.

(405)獲取青海菜寡醣萃取物:俟完成凍乾處理後,即會在各該不鏽鋼凍乾盤中形成凍乾之青海菜多醣水解液粉末,此即為青海菜寡醣萃取物(MO),嗣,以無菌操作方式(以滅菌過之藥杓),迅速地將MO刮入至已滅菌且已知重量之離心管中避免吸濕,再以電子天平秤重且予以標示為MO後,即能儲存至一乾燥箱內,靜待後續使用。 (405) Obtain Qinghai Vegetable Oligosaccharide Extract: Once the freeze-drying process is completed, a freeze-dried Qinghai Vegetable Polysaccharide Hydrolysate powder will be formed in each stainless steel freeze-drying tray, this is Qinghai Vegetable Oligosaccharide Extract (MO ), 嗣, aseptically (with sterilized medicine scoop), quickly scrape MO into a sterilized centrifuge tube of known weight to avoid moisture absorption, and then weigh it with an electronic balance and mark it as MO , It can be stored in a dry box, waiting for subsequent use.

嗣,發明人為了確認EFT、MO及二者在不同複合比例下所形成之複合材料(EFT/MO)的化學組成及生化特性,尚特別將各該臺灣鯛發酵凍乾萃取物EFT0、EFT10、EFT20及EFT30與該青海菜寡醣萃取物(MO)分別依不同的重量百分比(如:1:1或1:2),予以均勻混合,以令二者分別複合成複合材料(EFT/MO)1/1及(EFT/MO)1/2,且對各該臺灣鯛發酵凍乾萃取物EFT0、EFT10、EFT20及EFT30、該青海菜寡醣萃取物(MO)及各該複合材料(EFT/MO)11、(EFT/MO)12逐一進行如下所示的一系列實驗、分析及研究,以確認各該臺灣鯛發酵凍乾萃取物EFT0、EFT10、EFT20及EFT30、該青海菜寡醣萃取物(MO)及各該複合材料(EFT/MO)1/1、(EFT/MO)1/2等樣品的化學組成及生化特性: In order to confirm the chemical composition and biochemical characteristics of EFT, MO and the composite materials (EFT/MO) formed at different compounding ratios of EFT, MO and the two, the fermented freeze-dried extracts EFT0, EFT10, EFT20, EFT30 and the Qinghai vegetable oligosaccharide extract (MO) are mixed according to different weight percentages (for example: 1:1 or 1:2), so that the two are combined into a composite material (EFT/MO) 1/1 and (EFT/MO)1/2, and for each of the Taiwan sea bream fermented freeze-dried extracts EFT0, EFT10, EFT20 and EFT30, the Qinghai vegetable oligosaccharide extract (MO) and each composite material (EFT/ MO)11, (EFT/MO)12 carry out a series of experiments, analysis and research as shown below to confirm each of the fermented freeze-dried extracts of the Taiwan sea bream EFT0, EFT10, EFT20 and EFT30, the Qinghai vegetables oligosaccharide extract (MO) and the composite materials (EFT/MO) 1/1, (EFT/MO) 1/2, etc. Chemical composition and biochemical characteristics:

1、可溶性蛋白質含量的測定:本發明係以Sigma公司販售的lowry kit,測量各該樣品的可溶性蛋白質的含量,其作法係先將各該樣品粉末配置成濃度為20毫克/毫升的樣品溶液,再取1毫升的樣品溶液加入至1毫升的Lowry Reagent,均勻混合後,靜置20分鐘,再加入0.5毫升的Folin & Ciocalteu's Phenol Reagent的Working Solution,俟均勻混合後,再靜置30分鐘,取1.5毫升以分光光度計測量750nm的吸光值。如此,由BSA標準物質得到之標準檢量線即能換算出各該樣品的可溶性蛋白質含量,其單位為mg/g。 1. Determination of soluble protein content: The present invention uses the lowry kit sold by Sigma to measure the soluble protein content of each sample. The method is to first configure each sample powder into a sample solution with a concentration of 20 mg/ml , Then take 1 ml of the sample solution to 1 ml of Lowry Reagent, mix it uniformly, let it sit for 20 minutes, then add 0.5 ml of Folin & Ciocalteu's Phenol Reagent Working Solution, let it mix for 30 minutes, Take 1.5 ml and measure the absorbance at 750 nm with a spectrophotometer. In this way, the standard calibration curve obtained from the BSA standard substance can convert the soluble protein content of each sample, and the unit is mg/g.

2、游離胺基酸含量的測定(Doi et al.,1981參照):本發明係以Ninhydrin法,測量各該樣品的游離胺基酸含量,其作法係將各該樣品粉末配置成濃度為50毫克/毫升的樣品溶液,再取0.5毫升的樣品溶液加入至1毫升的Cd-ninhydrin reagent(即,0.8公克ninhydrin加入至80毫升無水 乙醇及10毫升醋酸的混合液中,最後,再添加至1公克CdCl2.1/2 H2O溶於1毫升去離子水的混合液中),在攝氏84度的水浴下加熱5分鐘後,以分光光度計測定在507nm的吸光值如此,由Leucine標準物質得到之標準檢量線即能換算出各該樣品的游離胺基酸含量,其單位為mg/g。 2. Determination of free amino acid content (Doi et al., 1981 reference): The present invention uses the Ninhydrin method to measure the free amino acid content of each sample, and its method is to configure each sample powder to a concentration of 50 Mg/ml of sample solution, then 0.5 ml of sample solution was added to 1 ml of Cd-ninhydrin reagent (ie, 0.8 g of ninhydrin was added to a mixture of 80 ml of absolute ethanol and 10 ml of acetic acid, and finally, to 1 Grams of CdCl2. 1/2 H2O dissolved in a mixture of 1 ml of deionized water), after heating in a water bath at 84 degrees Celsius for 5 minutes, the absorbance at 507nm was measured with a spectrophotometer. The standard calibration line can convert the free amino acid content of each sample, and the unit is mg/g.

3、胜肽含量的測定(Church et al.,1983參照):本發明係先配置o-Phthaldialdehyde的混合溶液,其作法係取25毫升的100mM sodium tetraborate、2.5毫升的20% sodium dodecyl sulphate(SDS)、1毫升的OPA(即,40毫克o-Phthaldialdehyde溶於1毫升的甲醇中)及100μL的β-mercaptoethanol,且將該等藥劑逐一倒入至一棕色定量瓶中,並以去離子水定溶至50毫升;然後,取適量的各該樣品,以去離子水溶解並定溶至10毫升,經0.2μm與5,000Da(Millipore,Bedford,MA,U.S.A.)濾膜過濾與適當稀釋後,取25μL的稀釋溶液加入含有1毫升的o-Phthaldialdehyde混合溶液至1.5毫升的石英管中,俟均勻混合再於室溫下靜置2分鐘後,以分光光度計測定在340nm的吸光值,如此,由Leu-Gly標準物質得到的標準檢量線即能換算出各該樣品的胜肽含量其,單位為mg/g。 3. Determination of the content of peptides (Church et al., 1983 reference): The present invention first configures a mixed solution of o-Phthaldialdehyde. Its method is to take 25 ml of 100 mM sodium tetraborate and 2.5 ml of 20% sodium dodecyl sulphate (SDS ), 1 ml of OPA (that is, 40 mg of o-Phthaldialdehyde dissolved in 1 ml of methanol) and 100 μL of β-mercaptoethanol, and pour these agents into a brown quantitative bottle one by one, and set with deionized water Dissolve to 50 ml; then, take an appropriate amount of each sample, dissolve in deionized water and dissolve to 10 ml, filter through 0.2 μm and 5,000 Da (Millipore, Bedford, MA, USA) filter membrane and properly dilute, take 25 μL of the diluted solution was added to a 1.5 ml quartz tube containing 1 ml of o-Phthaldialdehyde mixed solution, and after uniform mixing and then allowed to stand at room temperature for 2 minutes, the absorbance at 340 nm was measured with a spectrophotometer. The standard calibration curve obtained by the Leu-Gly standard substance can convert the peptide content of each sample, and the unit is mg/g.

4、ACE抑制能力測定(Wu and Ding et al.,2002參照):按,ACE在體外條件下,能夠分解馬尿酸-組氨醯-亮氨酸(HHL),產生馬尿酸(HA),HA在228nm處有明顯的吸收波峰,因此,本發明即藉採用HA的生成量,據以評估各該樣品對ACE的抑制作用(Phensri T et al.,2005參照),其作法係以硼酸加NaCl緩衝溶液,取代各該樣品的吸光值,做為控制組。ACE的抑制能力分析是依據Wu and Ding(2002參照)所述及的方法予以修飾而成,係以Luna C18的管柱(4.6mm×250mm,5μm),50%甲 醇(含0.1%的三氟醋酸)作為移動相,流速0.8mL/min,在波長228nm下測其吸光值,進而計據以算出各該樣品抑制ACE活性的百分比。 4. Determination of ACE inhibitory ability (referenced by Wu and Ding et al., 2002): According to, ACE can decompose hippuric acid-histidine-leucine (HHL) under in vitro conditions to produce hippuric acid (HA), HA There is an obvious absorption peak at 228nm. Therefore, the present invention uses the amount of HA produced to evaluate the inhibitory effect of each sample on ACE (Phensri T et al., 2005 reference). Its method is to use boric acid plus NaCl The buffer solution replaces the absorbance of each sample as the control group. The analysis of ACE's inhibitory ability was modified according to the method described in Wu and Ding (reference 2002). It was based on Luna C18 column (4.6mm×250mm, 5μm), 50% methanol (containing 0.1% trifluoro Acetic acid) was used as the mobile phase, with a flow rate of 0.8 mL/min, and its absorbance was measured at a wavelength of 228 nm, and then calculated to calculate the percentage of each sample that inhibited ACE activity.

俟本發明逐一完成前述測定後,即能獲得如下列表一所示各該樣品的化學組成與各項生化特性數據。 Once the present invention completes the aforementioned measurements one by one, the chemical composition and various biochemical characteristics data of each sample shown in Table 1 below can be obtained.

Figure 107128857-A0101-12-0023-3
Figure 107128857-A0101-12-0023-3

由表一所示各該樣品的化學組成與各項生化特性數據,即能清楚反映出本發明之各該樣品EFT0、EFT10、EFT20、EFT30、MO、(EFT30/MO)1/1及(EFT30/MO)1/2的下列化學組成及各項生化特性: The chemical composition and biochemical characteristics of each sample shown in Table 1 can clearly reflect the EFT0, EFT10, EFT20, EFT30, MO, (EFT30/MO) 1/1 and (EFT30 /MO)1/2 of the following chemical composition and various biochemical characteristics:

1、可溶性蛋白質含量:在本發明前述實驗組之各該樣品中,請參閱表一所示,發酵期間由0至10小時所製成的臺灣鯛發酵凍乾萃取物EFT0~EFT10,其可溶性蛋白質含量係由53.9±0.5大幅度地增加至134.9±0.1mg/g。惟,復請參閱表一所示,當發酵期間增加至30小時所製成的臺灣鯛發酵凍乾萃取物EFT30,其可溶性蛋白質含量則僅小幅度地增加 至140.6±0.6mg/g(p<0.05),據此,由前述數據的變化,應能清楚得知,隨著發酵期間的增加,乳酸菌中蛋白酶的作用時間愈長,各該臺灣鯛發酵凍乾萃取物EFT0、EFT10、EFT20及EFT30樣品中可溶性蛋白質的含量,亦顯然有增加的趨勢;其中,發酵期間由0增加至30小時所製成的臺灣鯛發酵凍乾萃取物EFT0及EFT30樣品,其可溶性蛋白質的含量明顯地由53.9±0.5大幅增加至146.6±0.6mg/g(如表一所示),然而,在發酵期間增加至10小時以後所製成的臺灣鯛發酵凍乾萃取物EFT10、EFT20及EFT30樣品,其可溶性蛋白質的含量(即,134.9±0.1、140.8±0.1及140.6±0.6mg/g)則無顯著的增加(如表一所示)。 1. Soluble protein content: In each sample of the aforementioned experimental group of the present invention, please refer to Table 1, the soluble protein of Taiwan sea bream fermented freeze-dried extract EFT0~EFT10 made from 0 to 10 hours during fermentation The content was greatly increased from 53.9±0.5 to 134.9±0.1mg/g. However, please refer to Table 1 for more information. The soluble protein content of Taiwan sea bream fermented freeze-dried extract EFT30, which was made up to 30 hours during fermentation, increased only slightly to 140.6±0.6mg/g(p< 0.05), based on the changes in the aforementioned data, it should be clear that as the fermentation period increases, the longer the protease action time in the lactic acid bacteria, the freeze-dried extracts EFT0, EFT10, EFT20 and EFT30 of each Taiwan sea bream fermentation The content of soluble protein in the sample also obviously has an increasing trend; among them, the content of soluble protein in the samples of the fermented freeze-dried extracts of Taiwan sea bream EFT0 and EFT30 made from 0 to 30 hours during fermentation obviously increased from 53.9± 0.5 was greatly increased to 146.6±0.6mg/g (as shown in Table 1), however, the soluble protein of the samples of the fermented freeze-dried extracts of Taiwan sea bream EFT10, EFT20 and EFT30 prepared after fermentation was increased to 10 hours later The contents (ie, 134.9±0.1, 140.8±0.1, and 140.6±0.6 mg/g) did not increase significantly (as shown in Table 1).

2、游離胺基酸含量:在本發明前述實驗組之各該樣品中,復請參閱表一所示,發酵期間由0至10小時所製成的臺灣鯛發酵凍乾萃取物EFT0~EFT10樣品,其游離胺基酸含量係由2.40±0.01大幅度地增加至16.8±0.32mg/g,然而,延長發酵時間至20小時所製成的臺灣鯛發酵凍乾萃取物EFT20樣品,其游離胺基酸的含量反而隨著發酵時間的增加而下降至13.5±0.01mg/g(如表一所示)其中,復請參閱表一所示,發酵期間由0增加至20小時所製成的臺灣鯛發酵凍乾萃取物EFT0及EFT20樣品,其游離胺基酸含量亦能由2.40±0.01明顯地增加至13.5±0.01mg/g,然而,在發酵期間增加至30小時所製成的臺灣鯛發酵凍乾萃取物樣品EFT30,其游離胺基酸的含量則會隨著發酵時間的增加而無明顯地增加,僅為14.4±0.15mg/g。發明人推測此一現象極可能是乳酸菌快速生長及增殖時需使用大量胺基酸作為氮源(Chen et al.,2003;Doeven et al.,2005叁照)所致,因此,在發酵初期(10至20小時期間)會造成游離胺基酸含量的減少。雖然,在 發酵20小時所製成的臺灣鯛發酵凍乾萃取物EFT20樣品,其游離胺基酸的含量為13.5±0.01mg/g;然而,當發酵至30小時所製成的臺灣鯛發酵凍乾萃取物EFT30樣品,其游離胺基酸含量14.4±0.15則無顯著(p<0.05)的增加。 2. Free amino acid content: In each of the samples of the aforementioned experimental group of the present invention, please refer to Table 1 for details. EFT0~EFT10 samples of Taiwan sea bream fermentation lyophilized extracts made from 0 to 10 hours during fermentation The content of free amino acid was greatly increased from 2.40±0.01 to 16.8±0.32mg/g. However, the free amino group of the EFT20 sample of Taiwan sea bream fermentation lyophilized extract made by prolonging the fermentation time to 20 hours Instead, the acid content decreased to 13.5±0.01mg/g (as shown in Table 1) with the increase of fermentation time. Please refer to Table 1 for more information, Taiwan bream made from 0 to 20 hours during fermentation Fermented freeze-dried extracts EFT0 and EFT20 samples, the free amino acid content can also be significantly increased from 2.40 ± 0.01 to 13.5 ± 0.01mg/g, however, increased to 30 hours during the fermentation of Taiwan sea bream fermentation frozen The dry extract sample EFT30, the content of free amino acid will not increase significantly with the increase of fermentation time, only 14.4 ± 0.15mg/g. The inventors speculate that this phenomenon is most likely caused by the rapid growth and proliferation of lactic acid bacteria that require the use of large amounts of amino acids as a nitrogen source (Chen et al., 2003; Doeven et al., 2005). Therefore, in the early stage of fermentation ( 10 to 20 hours) will cause a reduction in free amino acid content. Although, the EFT20 sample of Taiwan sea bream fermented freeze-dried extract prepared after 20 hours of fermentation had a free amino acid content of 13.5±0.01 mg/g; however, the Taiwan sea bream fermented frozen made after fermentation to 30 hours The dry extract EFT30 sample showed no significant (p<0.05) increase in free amino acid content of 14.4±0.15.

3、胜肽含量:在本發明前述實驗組之各該樣品中,復請參閱表一所示,發酵期間由0至10小時製成的臺灣鯛發酵凍乾萃取物EFT0~EFT10樣品,其胜肽含量雖會由12.6±0.5爆增至51.8±1.4mg/g。惟,當發酵期間延長至20小時所製成的臺灣鯛發酵凍乾萃取物EFT20樣品,其胜肽含量僅為53.2±0.6,此與EFT10的胜肽含量並無顯著差異(p<0.05),但是,隨著發酵期間的增加,如延長至30小時所製成的臺灣鯛發酵凍乾萃取物EFT30樣品的胜肽含量62.7±0.5,則有顯著增加的趨勢,其中,更以EFT30具有最高的胜肽含量,達62.7±0.5mg/g。此一結果清楚顯示,乳酸菌發酵期間的增加具有可明顯提高臺灣鯛發酵凍乾萃取物中的胜肽含量及生物活性的效果及趨勢,如:由12.6±0.5上升至62.7±0.5mg/g(p<0.05)。在相似的研究(Quirós et al.,2007參照)中亦顯示,牛乳以Enterococcus faecalis CECT5727在攝氏30度的環境下發酵0至48小時,其內胜肽含量將由0.5增加至3.0mg/mL。然而,由本發明的實驗組結果顯示,發酵期間至10小時所製成的臺灣鯛發酵凍乾萃取物EFT10樣品,其胜肽含量雖最高達12.6±0.5mg/g,但是,隨著發酵期間的增加,其所據製以成的臺灣鯛發酵凍乾萃取物EFT10、EFT20、EFT30樣品,其胜肽含量(51.8±1.4、53.2±0.6、62.7±0.5)反而陷入停滯,而無明顯的增加,發明人推測此一現象可能與不同乳酸菌的蛋白酶活性(蛋白酶、多肽酶、雙肽酶及胺肽酶等)不 同所造成的結果差異有關(陳,2007參照)。 3. Peptide content: In each of the samples of the aforementioned experimental group of the present invention, please refer to Table 1 below. The samples of the fermented lyophilized extract of Taiwan sea bream made from 0 to 10 hours during the fermentation period have the best results. Although the peptide content will increase from 12.6±0.5 to 51.8±1.4mg/g. However, when the fermentation period was extended to 20 hours, the EFT20 sample of Taiwan sea bream fermented freeze-dried extract had a peptide content of only 53.2±0.6, which was not significantly different from that of EFT10 (p<0.05). However, with the increase in the fermentation period, the peptide content of the EFT30 sample of Taiwan sea bream fermentation lyophilized extract made to extend to 30 hours has a significant increase trend, of which, EFT30 has the highest The peptide content reaches 62.7±0.5mg/g. This result clearly shows that the increase in the fermentation period of lactic acid bacteria can significantly improve the peptide content and biological activity in the freeze-dried extract of Taiwan sea bream, such as: from 12.6±0.5 to 62.7±0.5mg/g ( p<0.05). In a similar study (Quirós et al., 2007 reference), it was also shown that the milk was fermented with Enterococcus faecalis CECT 5727 at 30 degrees Celsius for 0 to 48 hours, and its peptide content will increase from 0.5 to 3.0 mg/mL. However, the results of the experimental group of the present invention show that the peptide content of the EFT10 sample of fermented freeze-dried Taiwan sea bream produced during the fermentation to 10 hours has the highest peptide content of 12.6±0.5 mg/g. However, the samples of Taiwan’s sea bream fermented freeze-dried extracts EFT10, EFT20, and EFT30, based on which they were prepared, had their peptide content (51.8±1.4, 53.2±0.6, 62.7±0.5) but stagnated without significant increase. The inventors speculate that this phenomenon may be related to the difference in results caused by different protease activities (proteases, polypeptide enzymes, dipeptidases, and aminopeptidases, etc.) of different lactic acid bacteria (Chen, 2007 reference).

4、抑制血管升壓素轉換酶之IC50值:由抑制ACE活性反應曲線可求得各該樣品的IC50值,IC50值係抑制ACE活性至50%時所需的胜肽濃度,此數值越低,表示抑制ACE的效果越佳。因此,發酵期間由10至20小時所製成的臺灣鯛發酵凍乾萃取物EFT 10及EFT 20樣品,其IC50值分別為1.04±0.08及1.40±0.01mg/mL,有明顯上升的現象,針對此,發明人推測可能係因乳酸菌蛋白酶的作用,導致部分有ACE抑制效果的胜肽水解,而造成抑制的效果變差。另一方面,發酵期間由10至30小時所製成的臺灣鯛發酵凍乾萃取物EFT10及EFT30樣品,其IC50值則分別為1.04±0.08及1.12±0.01mg/mL,兩組數據在統計上並無顯著差異(p<0.05)。 4, inhibition of vasopressin converting enzyme IC50 values of IC: ACE inhibiting activity of the response curve can be obtained the IC 50 value of each of the samples, the IC 50 values based upon the desired activity to ACE inhibitory concentration 50% peptides, this The lower the value, the better the effect of suppressing ACE. Thus, during the fermentation from the Taiwan porgy 10-20 hours made of fermented extracts were lyophilized samples the EFT EFT 10 and 20, an IC 50 values of 1.04 ± 0.08 and 1.40 ± 0.01mg / mL, with a marked increase in the phenomenon, In response to this, the inventors speculate that it may be due to the action of lactic acid protease that causes the hydrolysis of some of the peptides that have ACE inhibitory effect, resulting in the deterioration of the inhibitory effect. On the other hand, during the fermentation from the Taiwan porgy 10-30 hours made of fermented and lyophilized extracts EFT10 EFT30 sample, an IC 50 value of 1.04 ± 0.08, respectively, and 1.12 ± 0.01mg / mL, two sets of statistical data There was no significant difference (p<0.05).

據上所示,由於在本發明前述實驗組之各該樣品中,EFT 30的胜肽含量明顯高於EFT 0、EFT 10及EFT 20等樣品的胜肽含量,故,本發明在選擇EFT與MO樣品,依不同的重量百分比,令二者複合成活性胜肽複合材料時,即選擇以EFT 30作為最佳樣品,分別以1:1及1:2的重量百分比,與MO樣品均勻混合,而複合出活性胜肽複合材料(EFT/MO)1/1及(EFT/MO)1/2;嗣,分別針對EFT 30、MO、(EFT/MO)1/1及(EFT/MO)1/2進行ACE抑制活性分析後,其分析結果顯示,EFT 30的IC50值為1.12±0.01、MO的IC50值為1.09±0.03mg/mL、(EFT/MO)1/1的IC50值為1.08及(EFT/MO)1/1的IC50值為0.80mg/mL,由此結果清楚顯示,以(EFT 30/MO)1/2的IC50值(0.8mg/mL)為最低,意即,表示其對ACE的抑制效果最高,發明人推測其原因,係EFT與MO之活性胜肽間產生了協同 作用,而使之具有更佳的ACE抑制效果。 According to the above, in each sample of the aforementioned experimental group of the present invention, the peptide content of EFT 30 is significantly higher than that of the samples of EFT 0, EFT 10, and EFT 20. Therefore, the present invention selects EFT and When the MO sample is combined into an active peptide composite according to different weight percentages, EFT 30 is selected as the best sample, and the 1:1 and 1:2 weight percentages are respectively mixed with the MO sample uniformly. And the active peptide composite materials (EFT/MO) 1/1 and (EFT/MO) 1/2 are compounded; Si, for EFT 30, MO, (EFT/MO) 1/1 and (EFT/MO) 1 respectively /2 After analysis of ACE inhibitory activity, the analysis results showed that the IC 50 value of EFT 30 was 1.12±0.01, the IC 50 value of MO was 1.09±0.03 mg/mL, and the IC 50 value of (EFT/MO) 1/1 The IC 50 value of 1.08 and (EFT/MO) 1/1 is 0.80 mg/mL, which clearly shows that the IC 50 value (0.8 mg/mL) of (EFT 30/MO) 1/2 is the lowest, This means that it has the highest inhibitory effect on ACE, and the inventor speculates that the reason is that the synergistic effect between the active peptides of EFT and MO has a better ACE inhibitory effect.

此外,發明人為了確定各該樣品對人體的保健作用及效果,特別針對各該樣品EFT0、EFT10、EFT20、EFT30、MO(EFT/MO)11、(EFT/MO)12中GABA含量,進行測定;在本發明中係使用OPA衍生法分析各該樣品中γ-胺基丁酸(γ-aminobutyric acid,以下簡稱GABA)的含量,其作法係將100毫升的各該樣品溶液加入至500毫升的OPA working solution,俟震盪均勻,在室溫下反應2分鐘,且以0.22μm濾膜進行過濾後,即執行HPLC分析--取20μL注入C18管柱(5μm,250mm×4.6mm);移動相A為0.1M醋酸鈉(pH=6.7);移動相B為甲醇;梯度起始時A為90%;10分鐘後降至40%,維持此梯度達18分鐘;18分鐘後改為B移動相100%直到基線平穩,流速為0.8mL/min時,以紫外光-可見光偵測器於340nm下進行偵測;且偵測出如下列表二所示之數據結果,該結果清楚顯示,隨著發酵時間增加,各該EFT樣品中的GABA含量由發酵10小時至30小時,其含量可由12.92mg/100g提升至25.59mg/100g,提升幅度高達2倍;其中,又以EFT30具有最高的GABA含量;MO的GABA含量則為20.03mg/100g,其GABA含量相對地低於EFT30;各該複合材料(EFT/MO)1/1、(EFT/MO)1/2的GABA含量,則分別為25.79及24.46mg/100g,其中,(EFT30/MO)1/2的GABA含量較低,發明人推測其原因乃是該複合材料中寡醣含量的比例較高,導致GABA含量受到稀釋而降低。 In addition, in order to determine the health effects and effects of each sample on the human body, the inventors specifically determined the GABA content of each sample EFT0, EFT10, EFT20, EFT30, MO (EFT/MO) 11, and (EFT/MO) 12 In the present invention, the OPA derivation method is used to analyze the content of γ-aminobutyric acid (γ-aminobutyric acid, hereinafter referred to as GABA) in each sample. The method is to add 100 ml of each sample solution to 500 ml of OPA working solution, even shaking, react at room temperature for 2 minutes, and filter with 0.22μm filter, then perform HPLC analysis-take 20μL into C18 column (5μm, 250mm×4.6mm); mobile phase A 0.1M sodium acetate (pH=6.7); mobile phase B is methanol; A is 90% at the beginning of the gradient; it drops to 40% after 10 minutes, and the gradient is maintained for 18 minutes; after 18 minutes, it is changed to B mobile phase 100 % Until the baseline is stable, and the flow rate is 0.8mL/min, the UV-visible light detector is detected at 340nm; and the data results shown in Table 2 below are detected. The results clearly show that with the fermentation time Increase, the GABA content in each EFT sample from 10 hours to 30 hours of fermentation, its content can be increased from 12.92mg/100g to 25.59mg/100g, an increase of up to 2 times; Among them, EFT30 has the highest GABA content; MO The GABA content is 20.03mg/100g, and its GABA content is relatively lower than EFT30; the GABA content of each composite (EFT/MO) 1/1, (EFT/MO) 1/2 is 25.79 and 24.46, respectively. mg/100g, of which (EFT30/MO)1/2 has a low GABA content, the inventor speculates that the reason is that the ratio of oligosaccharide content in the composite material is high, resulting in a decrease in GABA content by dilution.

表二、臺灣鯛發酵凍乾萃取物、青海菜寡醣萃取物及二者複合物的GABA含量

Figure 107128857-A0101-12-0028-4
Table 2. GABA content of Taiwan sea bream fermented freeze-dried extract, Qinghai vegetable oligosaccharide extract and their complex
Figure 107128857-A0101-12-0028-4

按,GABA為一種抑制性的神經傳導物質,經由乳酸菌發酵可將麩胺酸轉換而形成GABA,且根據許多研究,均明確且清楚地指出此物質具有抑制血壓上升的作用(Inoue et al.,2003參照)。另,Sun等人(2009參照)從新疆發酵乳中(Xinjiang koumiss)分離出乳酸菌Lactobacillus helveticus ND01發酵脫脂乳24小時,其具有67.18%的ACE抑制率,GABA的含量則為165.11mg/L。此外,更有研究指出,其對原發性高血壓大鼠,以管餵灌食的方式,給予0.5mg/kg body weight的GABA,於灌食後第4小時其收縮壓平均下降了20.8mm Hg(Hayakawa et al.,2002)。以Lb.casei和Lc.lactis發酵之牛乳(其GABA濃度達10-12mg/100mL),給予輕度高血壓患者食用12週,於第8週時,其收縮壓平均下降了17.4±4.3mm Hg(Inoue et al.,2003參照)。雖然,由表二所示實驗數據結果清楚顯示,各該臺灣鯛發酵凍乾萃取物EFT 0、EFT 10、EFT 20及EFT 30等樣品及青海菜寡醣萃取物MO樣品的GABA含量相較低於發酵乳品,惟,發明人合理地推測,此一現象可能是發酵原料與發酵條件等不同因素所造成的結果差異。 According to GABA, an inhibitory nerve-conducting substance, glutamic acid can be converted to GABA by fermentation of lactic acid bacteria, and according to many studies, it is clearly and clearly pointed out that this substance has the effect of inhibiting the rise of blood pressure (Inoue et al., 2003 reference). In addition, Sun et al. (2009 reference) isolated lactic acid bacteria Lactobacillus helveticus ND01 fermented skim milk from Xinjiang fermented milk (Xinjiang koumiss) for 24 hours, which had an ACE inhibition rate of 67.18% and a GABA content of 165.11 mg/L. In addition, more studies have pointed out that, in the case of primary hypertensive rats, GABA with 0.5 mg/kg body weight was administered by tube feeding, and the systolic blood pressure decreased by 20.8 mm Hg on average 4 hours after the feeding (Hayakawa et al., 2002). Lb.casei and Lc.lactis fermented milk (with a GABA concentration of 10-12mg/100mL) was given to mildly hypertensive patients for 12 weeks. At 8 weeks, the systolic blood pressure decreased by an average of 17.4±4.3mm Hg (Refer to Inoue et al., 2003). Although, the experimental data results shown in Table 2 clearly show that the GABA content of the samples of the Taiwan sea bream fermented freeze-dried extracts EFT 0, EFT 10, EFT 20 and EFT 30 and the MO sample of Qinghai vegetable oligosaccharide extract are relatively low For fermented dairy products, the inventor reasonably speculates that this phenomenon may be the result of different factors caused by different factors such as fermentation raw materials and fermentation conditions.

最後,本發明為了確定各該樣品的蛋白質分子量分佈範圍,俾據以探討胜肽分子量的分布情形,尚分別針對各該樣品的蛋白質分子量 進行了膠體層析,其作法係將各該樣品調配成為適當濃度(50mg/mL)的樣品溶液,依序經0.2μm與5000Da濾膜的過濾後,再進行Sephadex G-25膠體層析,其中,針對EFT 0、EFT 10、EFT 20及EFT 30等樣品的膠體層析結果顯示,EFT 10的分子量範圍係介於2140~150Da;EFT 20的分子量範圍係介於1840~90Da;EFT 30的分子量範圍則係介於2030~100Da。此外,請參閱第4圖所示EFT 10、EFT 20與EFT 30層析結果的圖譜,在比較該等圖譜後,尚能發現其圖譜的波峰皆有向右移的現象,此一現象表示分子量有下降的趨勢,發明人推測此一趨勢極可能係因乳酸菌在發酵過程中分泌的蛋白酶水解了大分子蛋白質或胜肽,而導致小分子的胜肽含量增加。查,Sinha等人曾在進行Sephadex G-75膠體層析,以分析水解物中蛋白質的變化時亦發現,在未水解時以大分子蛋白質所佔的比例最多,惟,隨著水解時間的增加,蛋白質圖譜的波峰有向右移的現象,顯示小分子蛋白質的含量隨水解時間增加而上升(Sinha et al.,2007參照),發明人對此亦深表認同;針對MO、(EFT 30/MO)1/1及(EFT 30/MO)1/2的膠體層析結果,請參閱第5圖所示MO、(EFT 30/MO)1/1及(EFT 30/MO)1/2層析結果的圖譜,則顯示MO中的蛋白質分子量範圍係介於2030~330Da,(EFT 30/MO)1/1中的蛋白質分子量範圍係介於2140~110Da,(EFT 30/MO)1/2中的蛋白質分子量範圍則係介於2030~90Da,且可被劃分為如下列表三所示A至F共六個劃分區域,各該劃分區域的分子量分佈範圍又分別為2030~1150、1100~760、720~590、560~390、370~230及140~90Da;而各該劃分區域的胜肽濃度則分別為1.2、0.2、0.3、0.9、0.2及0.1mg/mL。 Finally, in order to determine the protein molecular weight distribution range of each sample of the present invention, in order to discuss the distribution of peptide molecular weight, colloidal chromatography was carried out on the protein molecular weight of each sample, and its method was to prepare each sample as The sample solution of appropriate concentration (50mg/mL) was filtered through 0.2μm and 5000Da filters in sequence, and then subjected to Sephadex G-25 colloid chromatography, in which, EFT 0, EFT 10, EFT 20, EFT 30 and other samples The results of colloidal chromatography show that the molecular weight range of EFT 10 is between 2140 and 150 Da; the molecular weight range of EFT 20 is between 1840 and 90 Da; and the molecular weight range of EFT 30 is between 2030 and 100 Da. In addition, please refer to the EFT 10, EFT 20, and EFT 30 chromatograms shown in Figure 4. After comparing the spectra, you can still find that the peaks of the spectra have shifted to the right. This phenomenon indicates the molecular weight There is a downward trend. The inventors speculate that this trend is most likely due to the protease secreted by the lactic acid bacteria during the fermentation process that hydrolyzes large-molecule proteins or peptides, resulting in an increase in the peptide content of small molecules. Cha, Sinha et al. used Sephadex G-75 colloidal chromatography to analyze the changes of protein in hydrolysate and found that the proportion of macromolecular protein was the largest when it was not hydrolyzed. However, as the hydrolysis time increased , The peak of the protein map shifts to the right, showing that the content of small molecule protein increases with the increase of hydrolysis time (Sinha et al., 2007 reference), the inventor also deeply agrees; for MO, (EFT 30/ MO) 1/1 and (EFT 30/MO) 1/2 colloidal chromatography results, please refer to the MO, (EFT 30/MO) 1/1 and (EFT 30/MO) 1/2 layers shown in Figure 5 The analysis of the results shows that the molecular weight range of the protein in MO is between 2030 and 330 Da, and the molecular weight range of the protein in (EFT 30/MO) 1/1 is between 2140 and 110 Da, (EFT 30/MO) 1/2 The molecular weight range of the protein is between 2030~90Da, and can be divided into six divided regions A to F as shown in Table 3 below. The molecular weight distribution of each divided region is 2030~1150 and 1100~760 respectively. , 720 ~ 590, 560 ~ 390, 370 ~ 230 and 140 ~ 90Da; and the peptide concentration of each of the divided areas is 1.2, 0.2, 0.3, 0.9, 0.2 and 0.1 mg/mL.

表三、複合材料(EFT 30/MO)1/2之各劃分物的分子量、胜肽濃度及ACE有

Figure 107128857-A0101-12-0030-5
Table 3. The molecular weight, peptide concentration and ACE of each division of composite material (EFT 30/MO) 1/2
Figure 107128857-A0101-12-0030-5

按,angiotensin converting enzyme(簡稱ACE)係一種血管緊張素轉換酶,主要具有下列二大功能:(1)催化血管緊張素I轉化為血管緊張素II;(2)使緩激肽失活。 According to press, angiotensin converting enzyme (ACE for short) is an angiotensin converting enzyme, which mainly has the following two major functions: (1) catalyze the conversion of angiotensin I to angiotensin II; (2) inactivate bradykinin.

ACE即因上列這兩種功能而成為治療高血壓、心力衰竭、2型糖尿病和糖尿病腎病等疾病的理想靶點。血管緊張素轉化酶抑制劑能減少血管緊張素II的生成,並增加緩激肽的活性。本發明經膠體層析分析各該樣品後,復請參閱上列表三所示,針對複合材料(EFT 30/MO)1/2主要可層析出六個劃分區域(A~F),其分子量分佈範圍分別為2030-1150、100-760、720-590、560-390、370-230及140-90Da;胜肽濃度分別為1.2、0.2、0.3、0.9、0.2及0.1mg/mL;且其ACE的抑制能力分別為83.5、27.2、58.9、1.3、26.2及7.6%;有效抑制百分比{IER=Inhibition(%)/Peptide concentration(mg/mL)}則分別為71.2、156.5、178.3、1.41、122.9及57.3%,如上列表三所示,其中,在各劃分區域中係以劃分物C的IER值為最高,因此, 收集C劃分區域進行進一步的RP-HPLC純化分析,請參閱第6圖所示,即能據以作為篩選與鑑定具抑制ACE活性之胜肽序列的參考依據。 ACE is the ideal target for the treatment of hypertension, heart failure, type 2 diabetes and diabetic nephropathy due to the two functions listed above. Angiotensin-converting enzyme inhibitors can reduce the production of angiotensin II and increase bradykinin activity. After analyzing each sample by colloidal chromatography in the present invention, please refer to Table 3 above. For composite materials (EFT 30/MO) 1/2, six divided regions (A to F) can be chromatographed, and their molecular weights The distribution ranges are 2030-1150, 100-760, 720-590, 560-390, 370-230 and 140-90Da; the peptide concentrations are 1.2, 0.2, 0.3, 0.9, 0.2 and 0.1mg/mL; and The inhibition capacity of ACE is 83.5, 27.2, 58.9, 1.3, 26.2 and 7.6%; the effective inhibition percentage {IER=Inhibition(%)/Peptide concentration(mg/mL)} is 71.2, 156.5, 178.3, 1.41, 122.9 And 57.3%, as shown in Table 3 above, in which the IER value of the partition C is the highest among the partitioned areas, therefore, the partition C is collected for further RP-HPLC purification analysis, please refer to Figure 6 , Which can be used as a reference basis for screening and identifying peptide sequences with inhibitory ACE activity.

然而,在本發明之前述測定、分析及研究中,各該樣品中對ACE抑制能力最高者為(EFT 30/MO)1/2的複合材料,該複合材料(EFT 30/MO)1/2經膠體層析分析後,主要可層析出六個劃分區域(A~F),其ACE的抑制能力分別為83.5、27.2、58.9、1.3、26.2及7.6%,有效抑制百分比{IER=Inhibition(%)/Peptide concentration(mg/mL)}則分別為71.2、156.5、178.3、1.41、122.9及57.3%,意即,在該複合材料(EFT 30/MO)1/2的劃分區域中,係以C劃分物的IER值為最高,因此,若欲針對其內所含活性胜肽之序列進行研究探討,僅需收集該C劃分區域的成份進行進一步的RP-HPLC純化分析,即能據以作為篩選與鑑定具抑制ACE活性之胜肽序列的參考依據。 However, in the aforementioned measurement, analysis, and study of the present invention, the composite material with the highest ACE inhibition ability of each of the samples was (EFT 30/MO) 1/2, and the composite material (EFT 30/MO) 1/2 After colloidal chromatography analysis, six divided regions (A~F) can be chromatographed, and their ACE inhibition capabilities are 83.5, 27.2, 58.9, 1.3, 26.2, and 7.6%, respectively, and the effective inhibition percentage {IER=Inhibition( %)/Peptide concentration (mg/mL)} is 71.2, 156.5, 178.3, 1.41, 122.9 and 57.3%, which means that in the divided area of the composite material (EFT 30/MO) 1/2, it is The IER value of the C partition is the highest, so if you want to study the sequence of the active peptide contained in it, you only need to collect the components of the C partition area for further RP-HPLC purification analysis, which can be used as Reference basis for screening and identifying peptide sequences with inhibitory ACE activity.

雖然,前述實驗結果顯示,本發明製成之臺灣鯛發酵粗萃發酵凍乾粉末EFT0、EFT10、EFT20、EFT30的GABA含量相較低於發酵乳品,此一現象極可能是導因於發酵原料及發酵條件等因素不同所產生的差異結果,惟,由表二所示結果卻能清楚反映,無論發酵時間長短,本發明實驗組製成之各該樣品EFT0、EFT10、EFT20、EFT30、MO、(EFT 30/MO)1/1及(EFT 30/MO)1/2內GABA含量,毫無置疑地已令其具備有效抑制血壓上升的保健功效及作用。 Although the foregoing experimental results show that the Taiwan sea bream fermented crude extract fermented freeze-dried powders EFT0, EFT10, EFT20 and EFT30 made in the present invention have a lower GABA content than fermented dairy products, this phenomenon is most likely due to the fermentation raw materials and The different results produced by different factors such as fermentation conditions, but the results shown in Table 2 can clearly reflect, regardless of the length of fermentation, the samples made by the experimental group of the present invention EFT0, EFT10, EFT20, EFT30, MO, ( The content of GABA in EFT 30/MO) 1/1 and (EFT 30/MO) 1/2 has undoubtedly made it have the health care effect and effect of effectively suppressing the rise of blood pressure.

綜上所述,本發明製成之該臺灣鯛發酵凍乾萃取物EFT0、EFT10、EFT20、EFT30、MO、(EFT 30/MO)1/1及(EFT 30/MO)1/2,經前述多項實驗已能清楚證實,不僅富含高品質且小分子量的活性胜肽,具備 有效抑制血壓上升的作用,尚具有極佳的ACE抑制率效,因此,令其得以被選擇作為高品質化粧品或保健食品(用以預防高血壓、心力衰竭、2型糖尿病及腎病等疾病)的理想成份,而能佳惠及確保消費者皮膚及身體的健康,從而令臺灣鯛冷凍魚片加工後所殘留的優質副產品及臺灣沿海垂手可得的青海菜,能因本發明而獲得更高附加價值的利用。 In summary, the fermented freeze-dried extracts of Taiwan sea bream made by the present invention, EFT0, EFT10, EFT20, EFT30, MO, (EFT 30/MO) 1/1 and (EFT 30/MO) 1/2, Many experiments have clearly confirmed that not only is it rich in high-quality, small-molecular-weight active peptides, but also has the effect of effectively suppressing blood pressure rise, it still has excellent ACE inhibition efficiency, so it can be selected as high-quality cosmetics or Ideal ingredients for health foods (used to prevent diseases such as hypertension, heart failure, type 2 diabetes, and kidney disease), and can benefit consumers to ensure the health of consumers' skin and body, so that the quality of Taiwan sea bream frozen fish fillets remaining after processing By-products and Qinghai vegetables, which are readily available along the coast of Taiwan, can be used for higher added value due to the present invention.

按,以上所述,僅為本發明最佳之一具體實施例,惟本發明之構造特徵並不侷限於此,任何熟悉該項技藝者在本發明領域內,可輕易思及之變化或修飾,皆可涵蓋在以下本案之專利範圍。 As mentioned above, the above is only one of the best embodiments of the present invention, but the structural features of the present invention are not limited to this, any person familiar with the art can easily think of changes or modifications in the field of the present invention , Can be covered in the patent scope of the following case.

301~305、401~405‧‧‧步驟 301~305, 401~405‧‧‧ steps

Claims (7)

一種由臺灣鯛發酵凍乾萃取物與青海菜寡醣複合成保健材料之製法,該製法係利用臺灣鯛冷凍魚片加工後殘留之副產品,且包括下列步驟:首先,將該副產品利用熱萃取方式進行萃取後,使用兩種乳酸菌分別對其萃取物執行一預定期間的發酵及凍乾處理,以獲得臺灣鯛發酵凍乾萃取物;其次,對青海菜進行熱萃取後,利用微生物酶對其萃取物進行一預定期間的水解及凍乾處理,以獲得青海菜寡醣萃取物;及最後,將該臺灣鯛發酵凍乾萃取物與該青海菜寡醣萃取物依一預定重量百分比複合成為一複合材料,該複合材料之γ-胺基丁酸的含量遠高過該臺灣鯛發酵凍乾萃取物與該青海菜寡醣萃取物本身的γ-胺基丁酸含量,且經膠體過濾層析分析,該複合材料內活性胜肽分子量分佈範圍約為90~2030Da,可被劃分成6個波峰區域,且以分子量為590~720Da的劃分區域對ACE的有效抑制百分比為最高;而該複合材料中游離胺基酸和胜肽含量亦較歷經不同發酵期間所得之該臺灣鯛發酵凍乾萃取物本身的游離胺基酸和胜肽含量值為高,該複合材料抑制ACE活性之IC 50值,亦遠較歷經不同發酵期間所得之該臺灣鯛發酵凍乾萃取物及該青海菜寡醣萃取物本身抑制ACE活性之IC 50值為低。 A method for preparing a health-care material from the fermented freeze-dried extract of Taiwan sea bream and oligosaccharides from Qinghai vegetables. The method uses the by-products remaining after processing of Taiwan sea bream frozen fish fillets, and includes the following steps: First, the by-products are extracted by heat After extraction, two kinds of lactic acid bacteria were used for fermentation and lyophilization of their extracts for a predetermined period of time to obtain fermented freeze-dried extracts of Taiwan sea bream; secondly, after hot extraction of Qinghai vegetables, they were extracted using microbial enzymes The material is subjected to hydrolysis and lyophilization for a predetermined period of time to obtain the Qinghai vegetable oligosaccharide extract; and finally, the Taiwan sea bream fermented lyophilized extract is compounded with the Qinghai vegetable oligosaccharide extract at a predetermined weight percentage to form a compound Materials, the content of γ-aminobutyric acid in the composite material is much higher than the content of γ-aminobutyric acid in the fermented freeze-dried extract of Taiwan sea bream and the oligosaccharide extract of Qinghai vegetables, and analyzed by colloidal filter chromatography The molecular weight distribution of active peptides in the composite material is about 90~2030Da, which can be divided into 6 peak regions, and the effective inhibition percentage of ACE is highest in the divided region with a molecular weight of 590~720Da; and in the composite material The content of free amino acids and peptides is also higher than that of the fermented freeze-dried extract of Taiwan sea bream obtained during different fermentation periods, and the IC 50 value of the composite material to inhibit ACE activity is also after much higher than that obtained during the fermentation of different fermentation Taiwan porgy and the extracts were freeze-dried oligosaccharide extracts were Qinghai dish itself IC ACE inhibiting activity of 50 is low. 如請求項1所述之製法,其中,該副產品為臺灣鯛冷凍魚片加工後之殘留物。 The manufacturing method according to claim 1, wherein the by-product is the residue after processing of Taiwan sea bream frozen fish fillets. 如請求項1所述之製法,其中,在對該青海菜進行熱萃取處理前,需先製備MMB培養基,其製備程序包括下列步驟:先準備經過一次純水潤洗過的2公升容量之三角錐形瓶兩個;嗣,分別於各該三角錐形瓶內配製具有預定成份的MMB培養基1.3公 嗣,分別於各該三角錐形瓶內配製具有預定成份的MMB培養基1.3公升,其中,該預定成份包括40.3克的Marine broth 2216、1.0克的Tris、6.0克的NaCL、1.0克的NaNO3、0.1克的KH2PO4、1.5克的Algal Powder及15毫升的熱萃液,且該熱萃液為青海菜熱萃液,該Algal powder為青海菜乾藻粉;以雙層鋁箔紙封住各該三角錐形瓶之瓶口;及對其加熱攪拌至二次沸騰後,置入一殺菌釜,在攝氏121度的環境下,執行15分鐘的滅菌處理,俟完成該滅菌處理後,待冷卻至室溫攝氏25度時,即完成該MMB培養基的製備。 The preparation method as described in claim 1, wherein, before hot extracting the Qinghai vegetable, an MMB medium needs to be prepared. The preparation procedure includes the following steps: first prepare a triangle with a capacity of 2 liters washed with pure water Two Erlenmeyer flasks; heirs, each prepared 1.3 liters of MMB medium with predetermined ingredients in each triangular Erlenmeyer flask, respectively prepared 1.3 liters of MMB medium with predetermined ingredients in each triangular Erlenmeyer flask, wherein, the The predetermined ingredients include 40.3 grams of Marine broth 2216, 1.0 grams of Tris, 6.0 grams of NaCL, 1.0 grams of NaNO3, 0.1 grams of KH2PO4, 1.5 grams of Algal Powder and 15 milliliters of hot extract, and the hot extract is Qinghai Vegetable hot extract, the Algal powder is dried algae powder of Qinghai vegetables; the mouth of each triangular conical bottle is sealed with double-layer aluminum foil paper; and after heating and stirring to the second boiling, it is placed in a sterilization kettle. Under the environment of 121 degrees Celsius, the sterilization process is performed for 15 minutes. After the sterilization process is completed, the preparation of the MMB medium is completed when it is cooled to 25 degrees Celsius at room temperature. 如請求項3所述之製法,在對該青海菜進行熱萃取處理前,尚需對該MMB培養基接種微生物酶,其接種程序包括下列步驟:利用接種環以無菌操作方式,自保存在攝氏-80度凍藏櫃中的P.vesicularis MA103與A.salmonicida MAEF108微生物酶之保存凍管,分別勾取一環,且三區劃線在MA培養基上,在攝氏26度的環境下,培養24小時,以作為第一次活化;嗣,再以接種環勾取一獨立分離菌落且三區劃線在新的MA培養基上,在攝氏26度的環境下,培養24小時,以作為第二次活化;接著,再以接種環勾取第二次活化之獨立分離菌落分別接種至13毫升之MB培養基中,以手輕微搖晃均勻後,置入直立式振盪培養箱中,在攝氏26度的環境下,以90rpm的速度振盪培養;及俟培養至菌落密度OD 600nm等於0.8~1.0時,以無菌操作方式,利用電動吸管分別吸取重量百分比為1%之MA103及MAEF108微生物酶,且分別將其加入至2公升容量之各該三角錐形瓶內已冷卻的該MMB培養基中,並在各該三角錐形瓶之瓶口套上適當大小的矽質瓶塞。 According to the manufacturing method described in claim 3, before the hot extraction treatment of the Qinghai vegetable, it is necessary to inoculate the MMB culture medium with microbial enzymes. The inoculation procedure includes the following steps: use the inoculation ring in a sterile manner and store it in Celsius- The freezing tubes of the P. vesicularis MA103 and A. salmonicida MAEF108 microbial enzymes in the 80-degree freezer are respectively ticked, and the three areas are lined on the MA medium, and cultured at 26 degrees Celsius for 24 hours, As the first activation; heir, and then use the inoculation loop to pick an isolated colony and three-division line on the new MA medium, in the environment of 26 degrees Celsius, culture for 24 hours, as the second activation; Then, Then use the inoculation loop to pick up the second activated independent colonies and inoculate them into 13 ml of MB medium. After shaking gently with your hands, place them in an upright shaking incubator at 90 rpm at 90 rpm. At a speed of shaking; and once cultured to a colony density of OD 600nm equal to 0.8 to 1.0, use a motorized pipette to aseptically absorb 1% by weight of MA103 and MAEF108 microbial enzymes and add them to a volume of 2 liters, respectively In each of the triangular conical flasks, the MMB medium has been cooled, and a silicon cork of appropriate size is placed on the mouth of each triangular conical flask. 如請求項4所述之製法,在對該青海菜進行熱萃取處理前,尚需對該MMB培養基執行水解處理,以產生粗酵素液,其水解處理程序係包括下列步驟:將該等三角錐形瓶置入至一直立式振盪培養箱中,設定在攝氏26度的環境下,以90rpm的速度振盪培養48小時,以誘導MA103及MAEF108之微生物酶能在MMB培養基中產生粗酵素液;以無菌操作方式將MA103及MAEF108在MMB培養基中所誘導產生之粗酵素液,分批裝入至已滅菌之離心管中約7分滿,再將各該離心管依序放入至已預冷至攝氏4度的離心機中,以14000xg的速度離心運轉30分鐘後,即能利用已滅菌之藥杓及適當的漏斗,自各該離心管獲取上清液部分;及嗣,將已滅菌之一抽氣過濾裝置與2公升之一血清瓶組裝成一體,對自各該離心管所獲取之上清液部分進行過濾,其中,為了預防該抽氣過濾裝置內0.45μm的濾膜在過濾時無法順利進行或被堵塞,會先分別將MA103、MAEF108所誘導產生之粗酵素液經離心過後的上清液部分倒入至已放上1.0μm濾膜之該抽氣過濾裝置,進行過濾,嗣,再接續將液體以0.5μm濾膜進行過濾;最後,始以0.45μm濾膜透過該抽氣過濾裝置,進行過濾,以過濾掉其中的大分子物質及毒素。 According to the manufacturing method described in claim 4, before performing hot extraction treatment on the Qinghai vegetable, it is still necessary to perform hydrolysis treatment on the MMB medium to produce a crude enzyme solution. The hydrolysis treatment procedure includes the following steps: Place the shaped bottle into a vertical vertical shaking incubator, set at 26 degrees Celsius and shake at 90rpm for 48 hours to induce the microbial enzymes of MA103 and MAEF108 to produce crude enzyme solution in MMB medium; Aseptic operation method, the crude enzyme solution induced by MA103 and MAEF108 in MMB medium is filled in batches into sterilized centrifuge tubes for about 7 minutes, and then each of the centrifuge tubes is sequentially placed until it has been pre-cooled to In a centrifuge at 4 degrees Celsius, after centrifugation at 14000xg for 30 minutes, the sterilized drug dipper and appropriate funnel can be used to obtain the supernatant portion from each centrifuge tube; and the heir, the sterilized one The air filter device is assembled with a 2 liter serum bottle to filter the supernatant part obtained from each centrifuge tube. Among them, in order to prevent the 0.45 μm filter membrane in the air suction filter device from filtering smoothly If it is clogged, the crude enzyme solution induced by MA103 and MAEF108 will be centrifuged into the supernatant to the suction filter device with a 1.0μm filter membrane for filtration, heir, and then continue. The liquid is filtered with a 0.5 μm filter membrane; finally, the 0.45 μm filter membrane is used to pass through the suction filter device to perform filtration to filter out the macromolecular substances and toxins therein. 如請求項5所述之製法,其中,對該青海菜進行熱萃取處理係包括下列步驟:取一20公升容量的塑膠桶,俟洗淨後裝入6公升的一次純水,且在該塑膠桶內加入重量百分比為15%的青海菜,適當搖晃該塑膠桶,俟青海菜與一次純水均勻混合成青海菜混合液後,蓋上塑膠桶之桶蓋,放入至一滅菌釜中,在攝氏121度的環境下,進行30分鐘的滅菌處理,俟完 成滅菌處理後,待該塑膠桶冷卻至室溫攝氏25度,即在該塑膠桶內製備了該青海菜熱萃液;及將該粗酵素液以重量百分比各為10%的比例,加入至6公升的該青海菜熱萃液中,即形成了7.2公升的青海菜待水解液。 The preparation method as described in claim 5, wherein the hot extraction process of the Qinghai vegetable includes the following steps: take a 20-liter plastic bucket, and after washing, fill it with 6 liters of pure water, and put it in the plastic Add 15% by weight of Qinghai vegetables to the barrel, shake the plastic barrel properly, and mix the Qinghai vegetables with pure water once to form a mixture of Qinghai vegetables, then put the lid on the plastic barrel and put it into a sterilization kettle. Sterilize for 30 minutes in an environment of 121 degrees Celsius. After the sterilization process is completed, wait for the plastic barrel to cool to 25 degrees Celsius at room temperature. That is, the hot extract of Qinghai vegetables is prepared in the plastic barrel; and The crude enzyme solution was added to 6 liters of the hot extract of Qinghai vegetables at a ratio of 10% by weight to form 7.2 liters of Qinghai vegetables to be hydrolyzed. 如請求項6所述之製法,其中,對該青海菜進行水解及凍乾處理,係包括下列步驟:將7.2公升的該青海菜待水解液放置在一迴轉式振盪器上,並在加強固定後,設定該迴轉式振盪器以90rpm速度振盪,待MA103及MAEF108所誘導出的該粗酵素液與該青海菜待水解液中的海藻發生酵素水解反應達48小時後,即形成了7.2公升的青海菜多醣水解液;嗣,將7.2公升之該青海菜多醣水解液依序分裝至1公升之血清瓶中,每瓶約分裝至750毫升即可,俟完成分裝後,將各該血清瓶放入至一殺菌釜中,在攝氏121度的環境下,執行15分鐘的滅菌處理,並在終止酵素水解反應後,對該青海菜多醣水解液進行取樣;將所取樣的該青海菜多醣水解液以無菌操作方式,倒入至已滅菌且包覆了二層鋁箔之一不鏽鋼凍乾盤中,每盤約可倒入700~800毫升之該青海菜多醣水解液,且將各該不鏽鋼凍乾盤分別放入至一凍乾機中,在攝氏-60度的環境下,執行3天的凍乾處理;及俟完成凍乾處理後,即會在各該不鏽鋼凍乾盤中形成凍乾之青海菜多醣水解液粉末,此即為該青海菜寡醣萃取物。 The manufacturing method according to claim 6, wherein the hydrolysis and freeze-drying of the Qinghai vegetable includes the following steps: placing 7.2 liters of the Qinghai vegetable to be hydrolyzed on a rotary oscillator and strengthening After that, the rotary oscillator was set to oscillate at a speed of 90 rpm. After the crude enzyme solution induced by MA103 and MAEF108 and the algae in the hydrolyzate of Qinghai vegetable had undergone an enzyme hydrolysis reaction for 48 hours, 7.2 liters of Qinghai Vegetable Polysaccharide Hydrolysate; Si, divide 7.2 liters of Qinghai Vegetable Polysaccharide Hydrolysate into 1 liter serum bottles in sequence, each bottle can be divided into approximately 750 milliliters. Put the serum bottle into a sterilization kettle, perform sterilization for 15 minutes under the environment of 121 degrees Celsius, and after the enzyme hydrolysis reaction is terminated, sample the polysaccharide hydrolysate of Qinghai vegetable; sample the Qinghai vegetable The polysaccharide hydrolysate is aseptically poured into a sterilized stainless steel freeze-dried pan covered with two layers of aluminum foil. Each pan can be filled with 700~800 ml of the Qinghai vegetable polysaccharide hydrolysate, and each Put the stainless steel freeze-drying trays into a freeze-drying machine and perform the freeze-drying treatment for 3 days under the environment of -60 degrees Celsius; and once the freeze-drying treatment is completed, it will be formed in each of the stainless steel freeze-drying trays The freeze-dried Qinghai vegetable polysaccharide hydrolysate powder is the extract of Qinghai vegetable oligosaccharide.
TW107128857A 2018-08-17 2018-08-17 Preparation method for compounding of fermented freeze-dried extract of Taiwan sea bream and Qinghai vegetable oligosaccharide extract into health care material TWI702006B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW107128857A TWI702006B (en) 2018-08-17 2018-08-17 Preparation method for compounding of fermented freeze-dried extract of Taiwan sea bream and Qinghai vegetable oligosaccharide extract into health care material

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW107128857A TWI702006B (en) 2018-08-17 2018-08-17 Preparation method for compounding of fermented freeze-dried extract of Taiwan sea bream and Qinghai vegetable oligosaccharide extract into health care material

Publications (2)

Publication Number Publication Date
TW202008895A true TW202008895A (en) 2020-03-01
TWI702006B TWI702006B (en) 2020-08-21

Family

ID=70766451

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107128857A TWI702006B (en) 2018-08-17 2018-08-17 Preparation method for compounding of fermented freeze-dried extract of Taiwan sea bream and Qinghai vegetable oligosaccharide extract into health care material

Country Status (1)

Country Link
TW (1) TWI702006B (en)

Also Published As

Publication number Publication date
TWI702006B (en) 2020-08-21

Similar Documents

Publication Publication Date Title
JP2019516412A (en) Low molecular weight collagen peptide and method for producing food composition using the same
CN102813113B (en) Composition capable of regulating human flora and immune function
TWI516280B (en) Use of chenopodium formosanum extract for manufacture of composition for enhancing secretion of collagen and preventing cutaneous aging
TW201609175A (en) Composition comprising collagen peptide, elastin peptide and proteoglycan
Chen et al. Recent advances in seafood bioactive peptides and their potential for managing osteoporosis
AU2019204868A1 (en) Production method of high bioactivity whole egg fermentation, and products and applications thereof
Kumar et al. In vitro anti-cancer, anti-diabetic, anti-inflammation and wound healing properties of collagen peptides derived from unicorn leatherjacket (Aluterus monoceros) at different hydrolysis
CN109287828A (en) A kind of tomato yeast tablet candy fruit and its preparation process
CN102491810B (en) Cordyceps militaris medium
CN110950925A (en) ACE inhibitory peptide with function of repairing nutrition activating cells and preparation method thereof
CN103734581B (en) Yak milk polypeptide nutrient powder being applicable to postoperative crowd&#39;s rehabilitation and preparation method thereof
CN104661671A (en) Gluten-related disorders
JP7144441B2 (en) Ground flounder having antioxidant and antihypertensive effects and method for producing the same
CN101503727B (en) Hyriopsis cumingii enzymolysis polypeptide, as well as preparation and application thereof
CN104642958A (en) Chinese yam and matrimony vine powder, and preparation method thereof
CN1456097A (en) Functional marine food and producing method thereof
TWI702006B (en) Preparation method for compounding of fermented freeze-dried extract of Taiwan sea bream and Qinghai vegetable oligosaccharide extract into health care material
CN100544616C (en) A kind of bitter buckwheat for three degressions health care powder and preparation method
CN102020711A (en) Casing smooth muscle collagen preparation method and functional study
Shinde et al. Overall Review on Therapeutic effects of Spirulina supplement
TWI718401B (en) Preparation method for extracting active peptides from by-products processed from Taiwan sea bream through fermentation and cultivation
CN1535620A (en) Preparation method of silkworm powder health-care food
JP5742060B2 (en) Immunostimulant containing component derived from genus leek and method for producing immunostimulator
Pietoyo et al. Enriching probiotics of feed using curcuma to increase growth rates of tilapia seeds (Oreochromis niloticus)
CN109170804A (en) A kind of microalgal polysaccharide Cardia Salt and preparation method thereof suitable for hypertensive patient

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees